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ORIGINAL RESEARCH
Effects of a Vegetarian Diet on 
Cardiometabolic Risk Factors, Gut 
Microbiota, and Plasma Metabolome in 
Subjects With Ischemic Heart Disease: 
A Randomized, Crossover Study
Demir Djekic , MD, PhD*; Lin Shi, PhD*; Harald Brolin, MSc; Frida Carlsson, MSc, RD; Charlotte Särnqvist, MD;  
Otto Savolainen, MSc, PhD; Yang Cao , PhD; Fredrik Bäckhed, MSc, PhD; Valentina Tremaroli, MSc, PhD; 
Rikard Landberg, MSc, PhD; Ole Frøbert, MD, PhD
BACKGROUND: A vegetarian diet (VD) may reduce future cardiovascular risk in patients with ischemic heart disease.
METHODS AND RESULTS: A randomized crossover study was conducted in subjects with ischemic heart disease, assigned to 
4-week intervention periods of isocaloric VD and meat diet (MD) with individually designed diet plans, separated by a 4-week
washout period. The primary outcome was difference in oxidized low-density lipoprotein cholesterol (LDL-C) between diets.
Secondary outcomes were differences in cardiometabolic risk factors, quality of life, gut microbiota, fecal short-chain and
branched-chain fatty acids, and plasma metabolome. Of 150 eligible patients, 31 (21%) agreed to participate, and 27 (87%)
participants completed the study. Mean oxidized LDL-C (−2.73 U/L), total cholesterol (−5.03 mg/dL), LDL-C (−3.87 mg/dL),
and body weight (−0.67 kg) were significantly lower with the VD than with the MD. Differences between VD and MD were
observed in the relative abundance of several microbe genera within the families Ruminococcaceae, Lachnospiraceae, and
Akkermansiaceae. Plasma metabolites, including l-carnitine, acylcarnitine metabolites, and phospholipids, differed in subjects
consuming VD and MD. The effect on oxidized LDL-C in response to the VD was associated with a baseline gut microbiota
composition dominated by several genera of Ruminococcaceae.
CONCLUSIONS: The VD in conjunction with optimal medical therapy reduced levels of oxidized LDL-C, improved cardiometa-
bolic risk factors, and altered the relative abundance of gut microbes and plasma metabolites in patients with ischemic heart 
disease. Our results suggest that composition of the gut microbiota at baseline may be related to the reduction of oxidized 
LDL-C observed with the VD.
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A western diet, characterized by high consumption of red and processed meat, refined carbohy-drates, and high calorie intake, has been asso-
ciated with increased risk of cardiovascular disease 
(CVD), including ischemic heart disease (IHD).1 A global 
change to an environmentally sustainable healthy diet, 
with considerable reduction of red meat consumption 
and increased consumption of plant-based foods, may 
save ≈11 million premature deaths each year.1
Epidemiological studies have shown that a vegetar-
ian diet (VD), primarily based on vegetables, legumes, 
fruit, grains, nuts, and occasionally eggs or dairy 
products, is associated with reduced incidence of, 
and mortality in, IHD as well as all-cause mortality.2,3 
Evidence from some randomized controlled trials sup-
ports the effectiveness of a plant-based diet in the pre-
vention of CVD4 and reduction in CVD risk factors.5-7 
A VD as part of an intensive lifestyle change has been 
shown to reverse coronary atherosclerosis in patients 
with IHD.8 Although mechanisms remain unclear, the 
effect of a VD in counteracting development of CVD 
might be attributed to reduced oxidative stress9,10 and 
to beneficial effects on factors such as blood lipids, 
glucose tolerance, and body weight.4,10,11 Most studies 
investigating the role of a VD in CVD prevention have 
comprised healthy participants and not consisted of 
a homogeneous group of patients on optimal medical 
therapy (eg, lipid- or blood pressure–lowering medica-
tion). The main barriers to adopting a VD have been 
reported to be enjoyment of eating meat and an unwill-
ingness to alter eating habits.12
Analysis of gut microbiota and the plasma metab-
olome before and after adoption of a VD offers the 
potential to gain mechanistic insight into nutritional in-
fluences on disease-related metabolic processes.13,14 
Research has shown impact of a VD on microbial taxa 
linked to CVD risk,14 and plant-based diets have been 
demonstrated to alter circulating metabolites, such as 
short-chain fatty acids (SCFAs) produced by gut fer-
mentation of dietary fiber and phosphatidylcholines in 
multiple biological pathways15-17 linked to CVD risk.18,19 
Carnitine, produced by ingestion of animal products, 
and its gut microbiota-derived metabolite, trimethyl-
amine N-oxide (TMAO), have been associated with 
CVD.20,21 A recent study reported increased risk of cor-
onary heart disease with higher TMAO concentrations. 
Regular consumption of plant-based foods could hy-
pothetically lower such risk.22 Individuals may respond 
differently to a given diet, and prediction models are 
being developed to determine the importance of an-
thropometrics, metabolomics, and microbiota to the 
outcomes of dietary intervention and to the design and 
implementation of personalized nutrition regimens.23,24 
Individual variation may contribute to inconsistency 
in results of dietary intervention studies.25,26 Recent 
reports have suggested that responses to dietary 
CLINICAL PERSPECTIVE
What Is New?
• Compared with a ready-made meat diet, an iso-
caloric ready-made vegetarian diet (VD) within
an individually adapted diet plan showed sec-
ondary prevention potential in patients with is-
chemic heart disease receiving optimal medical
treatment.
• After a 4-week intervention, subjects consum-
ing a VD showed significantly lower oxidized
low-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, total cholesterol, and
body mass index than those on a meat diet.
• Subjects on the VD exhibited reduced relative
abundance of fecal microbial taxa and plasma
metabolites associated with metabolic disease,
including cardiovascular disease, and with in-
creased taxa and metabolites associated with
lower cardiometabolic risk than those on a meat
diet.
What Are the Clinical Implications?
• A VD in conjunction with optimal medical ther-
apy improves levels of oxidized low-density
lipoprotein cholesterol, cardiometabolic risk
factors, and phospholipids associated with an
elevated risk of coronary events.
• A ready-made VD could be easily implemented
in individuals with a history of ischemic heart
disease to improve secondary prevention.
• Assessment of gut microbiota in follow-up of
patients with ischemic heart disease could help
to identify individuals potentially showing a fa-
vorable response to a VD.
Nonstandard Abbreviations and Acronyms
APOB apolipoprotein B
BCFA branched-chain fatty acid
BMI body mass index
CVD cardiovascular disease
HbA1c hemoglobin A1c
hs-CRP high-sensitivity C-reactive protein
IHD ischemic heart disease
LDL-C low-density lipoprotein cholesterol
MD meat diet
PCI percutaneous coronary intervention
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intervention might depend on the gut microbiota com-
position at baseline,23,24,27 as well as on metabotype.28 
However, little is known of whether individual baseline 
microbiota and/or metabolome are associated with the 
effect of a VD on metabolic CVD risk factors.
We conducted a 4-week randomized crossover 
study, using subject-specific dietary plans, to investi-
gate effects of a VD on CVD risk factors in subjects 
with a history of IHD treated by percutaneous coro-
nary intervention (PCI), compared with an isocaloric 
meat diet (MD). We aimed to determine the effect on 
oxidized low-density lipoprotein cholesterol (LDL-C) as 
the primary outcome and the secondary outcomes 
selected cardiometabolic risk factors, gut microbiota, 
and plasma metabolome, including TMAO, choline, 
l-carnitine, and acetyl-carnitine. We also explored
whether gut microbiota or plasma metabolome at
baseline could predict the level of response to a VD.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Study Participants
Patients with IHD who were treated with PCI and re-
ceiving optimal medical therapy were recruited from 
the outpatient clinic at the Department of Cardiology, 
Örebro University Hospital, Örebro, Sweden. 
Participant eligibility criteria were age >18 years, sta-
ble IHD, PCI conducted >1 month before study initia-
tion, and optimal medical therapy, including aspirin and 
cholesterol-lowering drugs. Exclusion criteria included 
age <18 years, unstable coronary disease, PCI treat-
ment during the preceding 30 days, inability to provide 
informed consent, already following a VD or vegan diet, 
vitamin B deficiency, known food allergy, previous bari-
atric surgery, or life expectancy <1 year.
All participants provided written informed consent. 
The study was performed in compliance with the 
Declaration of Helsinki, and the regional ethical review 
board in Uppsala, Sweden, approved the study (Dnr 
2016/456). The study is registered at Clini calTr ials.gov 
(NCT02942628).
Study Design
This was a prospective, open-label, randomized, con-
trolled crossover clinical trial. Subjects consumed 
isocaloric interventional diets, VD and MD, during 
4-week intervention periods separated by a 4-week 
washout period (Figure 1). The study was performed 
from September 2017 through June 2018. Subjects 
were randomly allocated to a preselected intervention 
sequence, VD-washout-MD or MD-washout-VD, at 
a 1:1 ratio to ensure balance of sequences. Clinical 
follow-up was performed on 4 occasions during 
the study, before and after each intervention period. 
Follow-up visits were scheduled between 7 am and 10 
am, and blood sampling was performed after overnight 
fasting. Patients were asked to collect stool samples in 
special sealed plastic containers on the day preceding 
each follow-up visit.
Diets
Dietary interventions were designed on the basis of eat-
ing habits in Sweden. They included food items avail-
able in standard grocery stores and were in agreement 
with the Nordic Nutrition Recommendations.29 The VD 
was a lacto-ovo-vegetarian diet allowing intake of eggs 
and dairy products. The MD refers to a conventional 
diet that was based on the average meat consumption 
in Sweden and corresponded to a daily intake of 145 g 
of meat, including red, white, and processed meats.30 
All subjects received a meal plan to follow through-
out the study. Lunches and dinners were provided as 
ready-made frozen meals (Tables S1 and S2). These 
meals were based on traditional Swedish recipes and 
produced and supplied by Dafgård, Källby, Sweden. 
Subjects visited the clinic on a weekly basis to col-
lect meals. At the first study visit, subjects met with 
a research dietitian who provided information on how 
to follow the individually energy-adjusted meal plans 
(Data S1). In addition to the 2 meals provided, subjects 
were asked to have breakfast, 2 snacks, and a side 
dish for the main course, every day. The meal plans 
included 5 to 6 options for breakfast, light meals, and 
side dishes. The nutrient composition of the diets was 
calculated using nutrition calculation software (Dietist 
Net Pro; Kost och Näringsdata AB, Bromma, Sweden) 
(Table 1).
Adherence to Dietary Intervention
The subjects completed a 3-day weighed food record 
before intervention, in the final week of each of the 
interventions, and at the end of the washout period 
(Table S3). During the intervention, patients were asked 
to complete a daily diary, recording whether they had 
consumed the provided lunch and dinner, which op-
tions they had chosen for breakfast and light meals, 
and if there were any deviations from the meal plan.
Primary and Secondary Outcomes
Difference in change in plasma oxidized LDL-C be-
tween diets was the primary outcome measure. 
Secondary outcomes included differences in change 
of cardiometabolic risk factors (lipids, hemoglobin A1c 
[HbA1c], hs-CRP [high-sensitivity C-reactive protein], 
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weight, body mass index [BMI], blood pressure, heart 
rate, quality of life, gut microbiota in fecal samples, 
fecal SCFAs and branched-chain fatty acids [BCFAs], 
plasma metabolome, and plasma levels of TMAO, cho-
line, l-carnitine, and acetyl-carnitine).
Oxidized LDL-C and Cardiometabolic Risk 
Factors
Venous blood samples were collected at the 4 study 
visits in evacuated plastic tubes (VACUETTE TUBE; 
Greiner Bio-One GmbH, Kremsmunster, Austria) and 
centrifuged in a cooling system at 1560g for 10 min-
utes at −40°C and stored at −80°C in aliquots until 
analyses. An ELISA kit (Mercodia, Uppsala, Sweden) 
was used for quantitative measure of plasma oxidized 
LDL-C levels, as described by Holvoet et al,31 with an 
intra-assay coefficient of variation <10% (mean, 3.74%) 
for most samples. Five samples showed a coefficient 
of variation >10%. Total cholesterol (TC), LDL-C, high-
density lipoprotein cholesterol, triglycerides, apoli-
poprotein A1, apolipoprotein B (APOB), hs-CRP, and 
Table 1. Macronutrient Profile of Prescribed Diet
Variable Energy, kcal Protein, g Carbohydrates, g Fat, g Saturated Fat, g Dietary Fiber, g
Vegetarian diet
According to meal plan* 1394 51.2 169.8 51 20.5 19.5
Intervention food† 999 38.4 104.8 45.7 17 15
Total‡ 2393 89.6 274.6 96.7 37.5 34.5
Meat diet
According to meal plan* 1318 48.9 168.7 43.8 15.2 22.4
Intervention food† 1076 41.8 102.4 55.9 22.2 10.7
Total‡ 2394 90.3 275.2 97.5 37.4 33.1
*Bread with topping, side dish, breakfast, and 0 to 3 snacks/light meals.
†Provided frozen dishes, including lunch and dinner.
‡Complete diet.
Figure 1. Schedule of study visits and participant flow. 
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HbA1c at each study visit were measured at the Clinical 
Chemistry Laboratory, Örebro University Hospital, ac-
cording to a standardized protocol (Data S1). Cutoff 
values of clinical markers routinely monitored after a 
cardiac event were based on European guidelines on 
CVD prevention in clinical practice32: LDL-C <70 mg/dL 
(<1.8 mmol/L), systolic blood pressure <130 mm Hg, 
diastolic blood pressure <80 mm Hg, and BMI <25 kg/
m2. For LDL-C, we used the  cutoff according to 
European guidelines during the study period, <70 mg/
dL. A digital automatic sphygmomanometer (Omron 
m6 ac; Omron Healthcare Co, Ltd, Kyoto, Japan) was 
used for blood pressure and heart rate measurements. 
Body height was measured at baseline, and body 
weight was measured at the 4 study visits. Quality of 
life was assessed by using the EuroQoL 5-dimension 
questionnaire at all study visits, including a visual ana-
logue scale and measures of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression.33 
The Lund-Malmö equation was used to determine the 
estimated glomerular filtration rate.
Gut Microbiota, Fecal Fatty Acids, and 
Plasma Metabolome
Details of instrumental analysis and preprocessing of 
raw reads for 16S rRNA gene sequencing analysis, 
SCFA and BCFA, plasma metabolome, and concen-
trations of plasma TMAO, choline, l-carnitine, and 
acetyl-carnitine are described in Data S1.
Fecal samples collected in a sterile stool tube by 
the participant on the day before each follow-up visit 
and stored in the home freezer (≈−20°C) were brought 
to the clinic and stored at −80°C until extraction. DNA 
was extracted from samples by repeated bead beat-
ing and subjected to 16S rRNA gene sequencing in 
an Illumina Miseq instrument (2×250  bp paired-end 
reads, V2 kit; Illumina, San Diego, CA) after PCR am-
plification of the V4 region with the 515F and 806R 
primers. A total of 1264 zero-radius operational taxo-
nomic units (abundance ≥0.002%) in 102 samples was 
obtained (Figure  S1A), primarily represented by the 
phyla Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria (Figure S1B).
Concentrations of the SCFA acetate, propionate, 
and butyrate; BCFA isobutyrate and isovalerate; suc-
cinate; and lactate in fecal samples were determined 
using a gas chromatograph mass spectrometer 
(Agilent Technologies), as previously described.34
For untargeted metabolomics, plasma samples 
were deproteinized using ultracentrifugation and an-
alyzed by high-performance liquid chromatography– 
quadrupole time-of-flight mass spectrometry (Agilent 
Technologies).23 In total, 1882 metabolite features (a 
molecular entity with a unique mass/charge ratio and 
retention time, as measured by an instrument) with the 
coefficient of variation in quality control samples ≤30% 
were subjected to further analysis. Metabolite identifi-
cation was based on accurate mass (mass tolerance 
≤5 ppm) and tandem mass spectrometry fragmenta-
tion (mass tolerance ≤10 ppm) matched against online 
databases or the literature.
The concentrations of plasma TMAO, choline, l-car-
nitine, and acetyl-carnitine were analyzed by high-per-
formance liquid chromatography–mass spectrometry 
on an Exion UHPLC coupled to a QTRAP 6500+ tan-
dem mass spectrometry system, both from AB Sciex 
LLC (Framingham, MA).
Statistical Analysis
The sample-size calculation was based on previous 
studies in which a VD or food supplements (nuts, soy-
based cereal, or cranberry juice) were shown to reduce 
oxidized LDL-C by 10% compared with no interven-
tion.35,36 Considering similar effects in our study and a 
mean reduction of oxidized LDL-C of 9%, we needed 
to include 27 patients in a crossover design to be able 
to reject the null hypothesis that the experimental and 
control treatments were identical with a probability 
(power) of 0.80 and a type I error probability of 0.05. 
On the basis of an estimated 10% dropout rate, we 
therefore enrolled 31 subjects.
The effects of diets on oxidized LDL-C and car-
diometabolic outcomes were evaluated using a gen-
eralized linear mixed model that included a fixed 
effect of the diet, sequence of diet allocation, and 
their interaction. Missing values were imputed in an 
intention-to-treat analysis using the last observation 
carried forward for the subjects (n=2) who were ran-
domized but did not receive intervention and for the 
subjects who dropped out after the first intervention 
period (n=2). In addition, we performed on-treat-
ment analysis. A 2-sided P<0.05 was considered 
significant.
A Kruskal-Wallis test was applied to the observed 
number of microbial species, and the Faith phyloge-
netic diversity index was used to examine potential dif-
ferences in α diversity between results of the 2 diets. 
Principal coordinate analysis of the weighted and un-
weighted UniFrac distances or the Bray-Curtis dissim-
ilarity was used to analyze the overall composition of 
gut microbiota. A permutational multivariate ANOVA 
(Adonis) (n=9999) and analysis of similarities were 
used to assess the effect of the dietary intervention 
on principal coordinate analysis scores of β diversity 
metrics. To identify microbial taxa or plasma metabo-
lites discriminating VD from MD, a random forest mod-
eling approach based on multilevel data analysis was 
applied37,38 for pair-wise comparison of zero-radius 
operational taxonomic unit or metabolite levels of VD 
and MD (Figure S2, Data S1). The multilevel analysis 
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deals with dependent data structures and has been 
successfully used to exploit differences specific to diet 
in crossover intervention studies. Significance of mul-
tivariate models was assessed by permutation tests 
(n=100). A common baseline effect was assumed for 
both interventions, because no differences in bacte-
rial genera or plasma metabolome were observed 
between baseline and the end of the washout period 
(Figures S3 and S4).
We further assessed the effect of VD versus MD 
on each selected optimally discriminating zero-radius 
operational taxonomic unit or metabolite using gener-
alized linear mixed models (R package "lme4"). Fixed 
factors included diet, sequence of diet allocation, and 
their interaction with baseline value as covariate and 
subject as random factor. The same analysis was ap-
plied to the concentrations of fecal SCFAs and BCFAs. 
Spearman correlation coefficients were calculated for 
all correlation analyses. The P values were adjusted for 
multiple comparisons using the Benjamini-Hochberg 
false discovery rate, and a value of P<0.05 was con-
sidered significant.
In an exploratory analysis, we investigated whether 
gut microbiota configuration or plasma metabolome 
at baseline was associated with the influence of VD 
on metabolic risk factors, including levels of oxidized 
LDL-C, LDL-C, TC, and BMI. Random forest model-
ing37 was used to identify a panel of microbial taxa or 
plasma metabolites that could enable discrimination 
of potential responders (subjects who benefitted from 
VD compared with MD and showed within-individual 
difference in metabolic risk factors between VD and 
MD <0) from nonresponders (subjects in whom VD did 
not improve metabolic risk factors compared with MD 
and had within-individual difference in metabolic risk 
factors between VD and MD >0).
RESULTS
Study Population and Diet Adherence
Of 150 patients with a history of IHD treated with PCI 
and receiving optimal medical therapy who were in-
vited, 31 (21%) agreed to participate and were rand-
omized. Twenty-nine were men (94%), with a median 
age of 67  years (range, 63–70 years) and a median 
BMI of 27.5 kg/m2 (Table 2). Two subjects dropped out 
because of difficulties adhering to the diet, one be-
cause of influenza and one because of cholangitis. 
Twenty-seven subjects completed the study (Figure 1). 
Before enrollment, 12 (39%) subjects had experienced 
an ST-segment–elevation myocardial infarction; 12 
(39%) had experienced a non–ST-segment–eleva-
tion myocardial infarction; 3 (10%) had unstable; and 
5 (16%) had stable angina pectoris. All subjects were 
receiving statin therapy, 29 (94%) were treated with 
aspirin, and 20 (65%) received P2Y12 inhibitors (clopi-
dogrel or ticagrelor). During the study, the only change 
in medical therapy was addition of calcium channel 
blockers in 2 subjects. Both dietary interventions were 
well tolerated, and overall adherence based on the 
self-reported diaries was 88% for both interventions; 
however, there was a difference in adherence with re-
spect to snacks (Table S4). On the basis of the 3-day 
food records, there was no significant difference in the 
intake of macronutrients; however, there was a differ-
ence in intake of fiber (Table S3).
Effects on Oxidized LDL-C and 
Cardiometabolic Risk Factors
Subjects consuming the VD showed significantly lower 
mean oxidized LDL-C compared with MD (−2.73 U/L) 
(P=0.02) (Figure 2, Table 3). A significant decrease from 
baseline of oxidized LDL-C after VD intervention was 
observed, whereas no difference was found after MD 
(Figure 2, Figure S4).
Subjects on the VD showed lower mean TC 
(−5.03  mg/dL/−0.13  mmol/L) (P=0.01), LDL-C 
(−3.87  mg/dL/−0.10  mmol/L) (P=0.02), body weight 
(−0.67 kg) (P=0.008), and BMI (−0.21 kg/m2) (P=0.009) 
compared with subjects on the MD (Figure  2, 
Table 3). No difference between diets was observed 
for high-density lipoprotein cholesterol, triglycerides, 
APOB, apolipoprotein, APOB/apolipoprotein A1 ratio, 
HbA1c, hs-CRP, blood pressure, heart rate, quality of 
life, or the number of subjects reaching guideline val-
ues of clinical markers LDL-C, blood pressure, and BMI 
(Table 3, Tables S5 and S6). Similar results were ob-
tained by the on-treatment analysis (Table S7).
Compared with baseline, both the VD and MD 
led to significantly lower mean values of TC (−7.8% 
and −5.7%, respectively), LDL-C (−11.9% and −7.9%, 
respectively), high-density lipoprotein cholesterol 
(−6.5% and −6.3%, respectively), APOB (−9.0% 
and −3.8%, respectively), and APOB/apolipoprotein 
A1 ratio (−8.0% and −7.9%, respectively) (Table  3, 
Figure  S5). There were no differences from base-
line in triglycerides, apolipoprotein A1, HbA1c, body 
weight, BMI, hs-CRP, blood pressure, heart rate, 
quality of life, or number of subjects reaching clinical 
marker guideline values after the 2 diet interventions 
(Table 3 and Tables S5 and S6).
Effects on Gut Microbiota, Fecal SCFAs 
and BCFAs, and Plasma Metabolome
The diets did not alter either richness or overall 
composition of gut microbiota at the phylum level 
(Figures  S6 and S7) but differed with respect to 
the relative abundance of several microbial genera 
(Figure  S8, Table  S8). Multilevel predictive mode-
ling revealed 46 microbial genera with the potential 
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to distinguish VD from MD (Figure  3A), most be-
longing to the families Ruminococcaceae (n=13), 
Lachnospiraceae (n=11), and Eggerthellaceae (n=4). 
Among them, 12 genera differed in VD and MD 
when individually assessed by univariate analysis 
(Figure 3A, Table S8).
The fecal concentrations of acetate, propionate, bu-
tyrate, isobutyrate, and isovalerate were 4% 10%, 5%, 
3%, and 6% higher, respectively, after 4 weeks of a VD 
than after MD. These results did not reach significance 
(Table S9).
The plasma metabolome differed significantly 
with diet (Figure  S9). Thirty-three plasma metab-
olites distinguished VD from MD with a predictive 
accuracy of 95%, among them acylcarnitine me-
tabolites and several phosphatidylcholines and 
Table 2. Baseline Characteristics of the Study Population at First Randomization Intervention
Characteristics All (n=31) VD (n=16) MD (n=15)
Age, median (range), y 67 (63–70) 67 (65–70) 68 (61–70)
Sex, men, n (%) 29 (94) 15 (94) 14 (93)
History before enrollment
STEMI, n (%) 12 (39) 6 (35) 6 (40)
NSTEMI, n (%) 12 (39) 4 (25) 8 (53)
Instable angina, n (%) 3 (10) 3 (19) 0 (0)
Angina, n (%) 5 (16) 4 (25) 1 (7)
Type 2 diabetes mellitus, n (%) 2 (7) 2 (13) 0 (0)
Hypertension, n (%) 17 (55) 10 (63) 7 (47)
Drug treatment
Statins, n (%) 31 (100) 16 (100) 15 (100)
Ezetimibe, n (%) 7 (23) 4 (25) 3 (20)
ASA, n (%) 29 (94) 15 (94) 14 (93)
P2Y12 inhibitors, n (%) 20 (65) 8 (50) 12 (80)
β Blockers, n (%) 28 (90) 14 (88) 14 (93)
ACE inhibitors/ARBs, n (%) 27 (87) 13 (81) 14 (93)
CCBs, n (%) 11 (36) 6 (38) 5 (33)
Cardiometabolic risk factors and life quality
Weight, mean±SD, kg 84±11.0 86±13.6 83±8.6
BMI, mean±SD, kg/m2 28±2.9 28±3.3 27±2.5
Systolic BP, mean±SD, mm Hg 139±17.4 140±17.4 138±18.0
Diastolic BP, mean±SD, mm Hg 87±9.6 88±10.6 87±8.7
Heart rate, mean±SD, bpm 65.8±9.2 65.1±9.2 66.5±9.5
EQ-5D VAS, mean±SD 80±10.7 78±11.2 82±10.2
Oxidized LDL-C, mean±SD, U/L 40.9±11.7 39.4±11.7 42.1±11.8
Total cholesterol, mean±SD, mg/dL 133.4±23.2 135.7±28.2 130.7±17.0
LDL-C, mean±SD, mg/dL 62.3±16.8 62.3±19.1 62.3±14.7
HDL-C, mean±SD, mg/dL 48.7±13.0 50.6±15.9 46.5±9.0
Triglycerides, mean±SD, mg/dL 94.0±29.8 93.7±32.3 94.2±28.0
APOB, mean±SD, g/L 0.7±0.1 0.7±0.1 0.7±0.1
APOA1, mean±SD, g/L 1.4±0.2 1.4±0.2 1.4±0.1
APOB/APOA1 ratio, mean±SD 0.5±0.1 0.5±0.1 0.5±0.1
HbA1c, median (range), mmol/mol 39 (36–40) 39 (36–42) 39 (36–40)
hs-CRP, median (range), mg/L 0.7 (0.5–1.7) 0.8 (0.4–1.7) 0.7 (0.4–1.7)
eGFR, mean±SD, mL/min per 1.73 m2 76.4±9.7 75.1±7.6 77.7±11.7
Data are presented as median (interquartile range), number (percentage), or mean±SD. To convert cholesterol markers to millimoles per liter, multiply 
by 0.02586. To convert triglycerides to millimoles per liter, multiply by 0.01129. ACE indicates angiotensin-converting enzyme; APOA1, apolipoprotein A1; 
APOB, apolipoprotein B; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; bpm, beats per minute; 
CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; EQ-5D, EuroQoL 5-dimension questionnaire (self-reported quality of life); HbA1c, 
hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MD, meat 
diet; NSTEMI, non–ST-segment–elevation myocardial infarction; P2Y12 inhibitor, clopidogrel or ticagrelor; STEMI, ST-segment–elevation myocardial infarction; 
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phosphatidylethanolamines (Figure  3B, Table  S10). 
When assessed individually using univariate statis-
tics, 28 of 33 metabolites were significantly different 
from MD in VD (Figure 3B).
We found a significant difference in plasma l-carni-
tine (−14.77 μmol/L) (95% CI, −21.13 to −8.71 μmol/L; 
P<0.001), but not in TMAO, acyl-carnitine, or choline, 
between the MD and VD (Figure 4).
The plasma concentration of TMAO and l-car-
nitine was lower after VD compared with base-
line (−1.90  μmol/L [95% CI, −2.87 to −0.93 μmol/L; 
P<0.001] and −14.46 μmol/L [95% CI, −24.75 to −4.17 
μmol/L; P<0.01]). The concentration of choline in-
creased with the VD (3.09 μmol/L; 95% CI, 1.06–5.12 
μmol/L; P=0.001) (Figure 4, Figure S10).
We observed multiple correlations of changes in mi-
crobiota, metabolites, and cardiometabolic risk factors 
with diet (Table 439-48, Table S11, Figure S11). However, 
no correlation remained significant after correction for 
multiple testing. No correlations were observed be-
tween fecal SCFAs or BCFAs and assessed clinical 
risk factors.
Baseline Gut Microbiota and Plasma 
Metabolites Associated With Clinical 
Outcome Response to the VD
Although we found significantly lower mean oxidized 
LDL-C and BMI after VD compared with MD, we ob-
served substantial interindividual difference in re-
sponse to dietary intervention (Figure  5, Figure  S12). 
Oxidized LDL-C and BMI were lower in 14 and 13 re-
sponders (subjects who benefitted from VD compared 
with MD and showed within-individual difference in 
Figure 2. Changes in oxidized low-density lipoprotein cholesterol (LDL-C) and cardiometabolic risk factors according to 
dietary intervention.
Mean change in oxidized LDL-C (A), total cholesterol (TC) (B), LDL-C (C), and weight (D) before and after each intervention. Error 
bars indicate SEM. ΔVD vs ΔMD indicates differences in risk factors between vegetarian diet (VD) and meat diet (MD) obtained using 
linear mixed-effects models adjusted for sequence of diet randomization and intervention period. *P<0.05, **P<0.01, ***P<0.001. Post, 
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metabolic risk factors between VD and MD <0), re-
spectively, after VD than after MD, whereas 6 and 7 
nonresponders exhibited higher oxidized LDL-C and 
BMI, respectively, with MD than with VD. In an ex-
ploratory analysis, we found that baseline relative 
abundance of 14 genera could discriminate respond-
ers from nonresponders: oxidized LDL-C decreased 
with the VD in individuals with higher fecal relative 
abundance of genera of the Ruminococcaceae fam-
ily, Ruminococcaceae UCG.010, Ruminococcaceae 
UCG.002, Ruminococcus 1, Ruminococcaceae 
UCG.007, Hydrogenoanaerobacterium, and Barnesiella 
and with low abundance of GCA.900066575 and 
Flavonifractor. The response of BMI to the VD was not 
associated with a specific baseline gut microbiota con-
figuration (Figure S8). Plasma metabolites at baseline 
were not associated with any response to intervention 
(Figure S13).
DISCUSSION
In this randomized, controlled, crossover study in 
subjects with IHD, a 4-week VD showed lower oxi-
dized LDL-C and improved cardiometabolic risk fac-
tors compared with an isocaloric MD. The VD also 
influenced the relative abundance of microbial gen-
era and plasma metabolites that have shown links 
to metabolic disease.49-52 The change in oxidized 
LDL-C with the VD occurred in people with a specific 
baseline gut microbiota showing higher abundance 
of several genera in the families Ruminococcaceae 
and Barnesiella, a gut microbe that might play an 
Table 3. Effect of Dietary Intervention on Clinical Parameters
Clinical Parameters Pre-VD Post-VD Pre-MD Post-MD
Post-VD vs 
Post-MD* P Value*





































































































































































Data are presented as mean (95% CI) or as geometric mean [95% CI]. Within-group change P value was calculated with paired t test. APOA1 indicates 
apolipoprotein A1; APOB, apolipoprotein B; BMI, body mass index; BP, blood pressure; bpm, beats per minute; HbA1c, hemoglobin A1c; HDL-C, high-
density lipoprotein cholesterol; HR, heart rate; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MD, meat diet; TC, total 
cholesterol; and VD, vegetarian diet.
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important role in clearance of intestinal infections and 
immunomodulation.53,54
Diet Effects on Oxidized LDL-C and 
Cardiometabolic Risk Factors
Conversion of LDL-C to oxidized LDL-C plays a cen-
tral role in the development and progression of fatty 
streaks and atherosclerotic plaques.55 Untreated in-
dividuals with IHD have significantly higher levels of 
oxidized LDL-C compared with people free of IHD.31 
Independent of traditional cardiovascular risk fac-
tors, elevated oxidized LDL-C has been shown to be 
a strong predictor of future IHD events.6 It has recently 
been suggested that oxidized LDL-C leads to unsta-
ble coronary plaques via complex mechanisms of lipid 
mediators.56 Our study indicates that, in subjects with 
IHD on optimal medical therapy, change in diet was 
accompanied by a decrease in oxidized LDL-C; hence, 
adoption of a VD in such patients could be of clini-
cal importance. Studies of the link between diet and 
oxidized LDL-C are scarce; however, a clinical trial of 
healthy subjects with no diagnosed CVD showed oxi-
dized LDL-C 5.4 U/L lower after 3 months of a gluten-
free vegan diet than seen in a nonvegan diet.35 We 
found that 4  weeks on a VD resulted in significantly 
lower oxidized LDL-C (−2.7 U/L) than with the MD in 
subjects with IHD treated with PCI, suggesting benefits 
of implementing VD intervention in addition to optimal 
medical therapy.
A recent meta-analysis of 11 randomized con-
trolled trials reported a lipid-lowering effect of VD in 
healthy subjects free of CVD.7 Most of the included 
trials comprised subjects not receiving lipid-lower-
ing drugs. The pooled estimated changes in TC and 
LDL-C were −13.9 and −13.1 mg/dL, respectively, but 
no significant effects were observed for triglycerides. 
These effects were greater than those found in the 
current study. Interventions in the trials included in 
the meta-analysis were of longer duration, and our 
subjects had low TC and LDL-C levels at baseline. 
More important, our results suggest an additive ef-
fect of VD on TC and LDL-C in subjects receiving lip-
id-lowering medication. A 4% decrease in LDL-C may 
result in a meaningful reduction of coronary events. 
In agreement with previous studies, we observed a 
reduction in body weight with the tested VD, sup-
porting a role for a VD on weight control in patients 
with IHD. The observed effects of VD on oxidized 
LDL-C and lipid profile may be partly attributed to 
weight loss.57 On the other hand, we observed the 
greatest change in oxidized LDL-C and lipid profile 
Figure 3. Gut microbiota and plasma metabolites discriminating the vegetarian and meat diets, and selected by multilevel 
random forest modeling.
Least-squares means and 95% CIs of abundance of zero-radius operational taxonomic units (A) and levels of metabolites (B) after 
4-week intervention of the vegetarian and isocaloric meat diet obtained from random forest multivariate modeling. Standardized 
values are presented for comparison. *Denotes microbial genera or metabolites significantly differing between meat and vegetarian 
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compared with baseline after the VD, despite no sig-
nificant change in weight in this group.
Previous studies have shown benefit of a VD with 
respect to blood pressure, HbA1c, and hs-CRP com-
pared with an omnivore diet,6,58,59 which was not sup-
ported by our study. The source of the lack of reduction 
in hs-CRP with the VD may be the fact that all study 
participants were treated with statins, which show an-
ti-inflammatory properties, or the lack of power to de-
tect changes in hs-CRP.
The baseline treatment did not influence the re-
sults, because of the crossover design of the study. 
Moreover, because no alterations in cholesterol-low-
ering drugs (statins or ezetimibe) were made during 
the study period, it is unlikely that medication had an 
impact on oxidized LDL-C or cholesterol measures. On 
the other hand, a change in antihypertensive therapy 
(calcium channel blockers) of 2 subjects may partly 
explain the lack of effect of VD on blood pressure com-
pared with MD.
Diet Effects on Gut Microbiota and 
Plasma Metabolome
The 4-week dietary intervention did not alter either 
the richness or the overall composition of the gut mi-
crobiota, in line with previous findings.60 However, we 
observed altered relative abundance of bacterial gen-
era that have been associated with human metabolic 
health status.13,15,39,40,46,61,62 For example, compared 
with MD, subjects consuming the VD exhibited higher 
relative abundance of the genus Akkermansia, shown 
to be enriched after intervention with prebiotic inulin 
and in polyphenol-rich diets.39 Akkermansia was also 
linked to beneficial effects on body fat distribution as 
well as fasting plasma glucose and triglyceride levels 
Figure 4. Changes in plasma concentration of trimethylamine N-oxide (TMAO), choline, l-carnitine, and acetyl-carnitine 
according to dietary intervention.
Boxplots (A through D) show the concentrations of the metabolites measured at baseline, after the vegetarian diet (VD) and the 
isocaloric meat diet (MD). Differences were assessed by paired t test. Least-squares means and 95% CIs of levels of metabolites (E) 
after 4-week intervention of VD and MD assessed by generalized linear modeling. Standardized values are presented for comparison. 
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in a 6-week interventional trial of caloric restriction in 
obese subjects.49
The levels of fecal SCFAs were measured to quantify 
microbiota fiber fermentation capacity. Previous stud-
ies have shown effects of a VD or vegan diet on en-
richment of SCFA-producing bacteria (eg, Roseburia, 
Ruminococcus, and Blautia) and subsequent increase 
in fecal SCFA levels, which may contribute to improved 
metabolic health.63,64 We found a trend of increased 
fecal SCFAs with the VD, consistent with the slightly 
higher increase of fiber intake compared with the MD. 
Fecal SCFA level is influenced by the quantity of in-
gested fiber as well as individual characteristics, includ-
ing composition of gut microbiota, intestinal gut transit, 
and rate of intestinal absorption.65 Therefore, a larger 
sample size and a greater difference in the ingested 
fiber content of the diets might have been required to 
show significant changes in SCFA levels. In the present 
study, we adjusted the MD meal plans to include higher 
fiber content of the side dishes, breakfast, and snacks 
to obtain daily dietary fiber intake similar to that of the 
VD compared with MD.
We also observed differences in plasma metabo-
lites after VD in subjects with IHD. Subjects consum-
ing the VD exhibited lower levels of the acylcarnitine 
metabolites 2-hydroxylauroylcarnitine and 2-methyl-
butyroylcarnitine, as well as of several phospholipids 
containing fatty acids C14:0, C16:0, C16:1, and C18:1. 
In addition to traditional risk factors, these metabolites 
may improve risk prediction for recurrent coronary 
events.66
The VD compared with MD resulted in a reduction 
of plasma l-carnitine, a metabolite found predomi-
nately in red meat, findings that support that most of 
the subjects were adherent to both interventions and 
verify the accuracy of the analysis. The conversion of 
l-carnitine to trimethylamine is gut microbiota depen-
dent,67 and trimethylamine is absorbed by the por-
tal system and transformed by the liver to TMAO, a 
potential proatherogenic compound.21,68 Although no 
significant difference was observed between diets in 
TMAO, both VD and MD were shown to reduce its 
plasma level compared with baseline. These changes 
may have been caused by the reduced energy intake 
Figure 5. Baseline gut microbiota associated with response to diets in reduction of oxidized low-density lipoprotein 
cholesterol (LDL-C).
A, Intraindividual difference in oxidized LDL-C between vegetarian diet (VD) and meat diet (MD) is presented. Responders were defined 
as participants who showed lower oxidized LDL-C after VD than after MD. Patients who had higher oxidized LDL-C after VD than after 
MD were considered as nonresponders. B, Discrimination of responders from nonresponders based on microbial genera at baseline. We 
applied random forest modeling on relative abundance of zero-radius operational taxonomic units (ZOTUs) at baseline. Of 20 individuals, 
17 could be successfully classified as responders or nonresponders. C, The optimal set of microbial genera for the successful classification 
(n=14). Relative abundance of ZOTUs for responders and nonresponders are presented. Boxes represent the interquartile range, and the 
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designed from individually adapted meal plans rather 
than dietary composition. However, the results 
should be interpreted with caution because others 
have showed a difference in TMAO levels between 
vegans and omnivores,18 and there might have been 
a lack of power in our study to detect significant 
changes. Moreover, the metabolic control and the 
renal function may interfere with TMAO levels,69 al-
though our study subjects had normal HbA1c and 
estimated glomerular filtration rate at baseline and 
the crossover design minimizes the likelihood of bias 
from confounding.
Our results support previously reported cor-
relation of TMAO with genus Bifidobacterium 
(r=−0.31; P=0.05), genera belonging to the family 
Ruminococcaceae (eg, Butyricicoccus: r=−0.42, 
P=0.01; and Intestinimonas: r=−0.40, P=0.02), and 
several unannotated species of Lachnospiraceae 
and Ruminococcaceae.18,51,68 These findings indicate 
that a short-term VD intervention might have influ-
enced the activity of the gut microbiota in people 
who are omnivorous.
We observed an effect of VD on potential links 
among plasma metabolites, bacterial genera, and 
CVD risk factors. The correlations did not reach sig-
nificance after false discovery rate correction for mul-
tiple testing, possibly because of the small number 
of participants and the similarity of microbial species 
in the gut microbiota. Our findings are consistent 
with previous studies52,66,70 and indicate that mecha-
nisms underlying the benefits of a short-term VD in-
tervention on CVD risk factors may be explained by 
modulation of the abundance and metabolism of gut 
microbes.39
Baseline Gut Microbiota Associated With 
Oxidized LDL-C Response to Diets
Our results underscore the role of individual gut mi-
crobiota in specific cardiometabolic risk factor re-
sponse to a diet,25-27 such as that of oxidized LDL-C. 
We observed no significant association of relative 
abundance of gut bacteria at baseline with change 
in BMI during the study, in agreement with a recent 
meta-analysis indicating a weak relationship between 
gut microbiota and BMI.71 However, we observed 
that several genera of the Ruminococcaceae, as 
well as the genus Barnesiella, were more abundant 
in individuals in whom oxidized LDL-C was reduced 
to a greater extent (responders) after a 4-week VD; 
whereas GCA900066575 in the Lachnospiraceae 
family was less abundant relative to levels in nonre-
sponders. Accumulating evidence supports a role of 
inflammation and the immune response in develop-
ment of atherosclereosis.72,73 Our results may sug-
gest an interaction between specific gut bacteria and 
a VD in reduction of oxidized LDL-C, a lipoprotein 
that has been found to contribute to atherosclerosis-
associated inflammation, activating both innate and 
adaptive immunity.54,74
Strengths and Limitations
The major strengths of the reported study include 
its crossover design, well-characterized subjects re-
ceiving optimal medical therapy, and a high rate of 
study completion. For future implementation, it is 
also a strength that the dietary interventions included 
ready-made main meals, because people often state 
that a VD is inconvenient and that they are unfamiliar 
with preparing vegetarian food. The availability of ac-
ceptable ready-made plant-based foods could facili-
tate secondary prevention.75 In our crossover study, 
effects were only attributed to differences in diet, 
we found no significant impact in the order of the 
2 dietary interventions, and there were no carryover 
effects.
The study has several limitations. First, the small 
sample size might have affected results with respect 
to clinical parameters, such as blood pressure, lipid 
and apolipoprotein biomarkers, and low-grade inflam-
mation. Second, most of our study participants were 
men, decreasing generalizability. Third, a short-term 
intervention period allows only limited conclusions 
on adherence and clinical impact of diet. Measures 
of oxidized LDL-C levels in plasma ex vivo may not 
precisely reflect levels in vivo, as highly oxidized parti-
cles are rapidly cleared by scavenger receptors in the 
liver and antioxidants in blood.44 We used a sandwich 
ELISA with a murine monoclonal antibody (mAb-4E6) 
directed against the oxidized antigenic determinants 
on the oxidized APOB molecule. This antibody may 
react with oxidized particles other than LDL-C, such 
as oxidized phospholipids and lipoproteins.76 The un-
targeted metabolomics approach did not include a 
comprehensive analysis of bile acids, which precluded 
further investigation into the potential mechanistic role 
of gut microbiota regulation of bile acid metabolism in 
the cardiometabolic effects of the VD. We found that 
bacterial genera in the families Ruminococcaceae and 
Lachnospiraceae, known to modulate bile acid pro-
file,77,78 correlated with TC. The association did not 
remain significant after correction for multiple testing. 
Finally, information on the micronutrient content of the 
ready-made dishes was lacking, and a potential dif-
ference in the diets might have influenced the study 
results.
CONCLUSIONS
Our study suggests cardiometabolic benefits of 
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subjects with ischemic heart diease on optimal medi-
cal treatment. The VD reduced levels of oxidized LDL-
C, LDL-C, TC, and body weight compared with MD. 
The VD intervention also influenced levels of several 
microbial genera and plasma metabolites known to be 
linked to metabolic health status, suggesting the role 
of host-microbiota cometabolism for benefits of VD in 
people with ischemic heart diease. The composition 
of gut microbiota at baseline may have been associ-
ated with the lower oxidized LDL-C seen with the VD, 
reinforcing the importance of implementing person-
alized approaches to nutrition in addition to medical 
treatment, for effective management of cardiovascular 
disease.
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Meal plan used in the study for meat diet 
• The energy level of the average diet was set at 2400 kcal per day. Adjustments will 
be made to accommodate individual requirements according to energy intake strata. 
Background information 
• In the VERDI study we want to investigate the effects on cardiometabolic risk factors 
of a lacto-ovo-vegetarian diet vs. a diet with meat in quantities corresponding to 
average meat intake in the Swedish population. You will, during two four-week-
periods, follow a meal plan adapted to your calorie requirements so that you do not 
lose weight during the trial. It is important that you follow the meal plan. 
Lunch and dinner 
• During two four-week-periods, you will be provided with frozen, ready-made dishes 
for lunch and dinner. You are advised to consume the entire meal. In addition, you 
are given an individual meal plan which you should strictly follow. 
Meal plan 
• You will eat breakfast, snacks, and side dishes according to the meal plan adjusted to 
meet your energy requirements. 
• The meal plan includes a number of alternatives for breakfast, snacks, and side 
dishes. 
• The side dishes consist mainly of bread with toppings and can be consumed along 
with the main dish for lunch and dinner or between meals. 
 
Please note 
• It is important that you complete the daily food diary. In the food diary you record 
which alternative you have chosen for breakfast, snack, and side dish. Please note 
any deviations from the meal plan. 
• It is important that you follow the meal plan, but you are allowed to deviate from it 
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Breakfast 600 kcal                                 Meal plan – Meat  
Each day choose one of the five breakfast alternatives below. Try to vary your choice from 
day to day. 
• Fill in the food diary and check the alternative you have chosen. 
• You do not have to eat the breakfast at any particular time, and you do not have to 
eat the entire breakfast at one time. 
1. Yoghurt with oat cereal, sunflower seeds and apple sauce. Sandwich with butter, 





Yoghurt (0.5% fat) 2.5 dl Sour milk (0.5% fat) 
Oat cereal 2 dl Bran flakes, rye cereal 
Sunflower seeds 1.5 tbsp Pumpkin seeds, nuts 
Applesauce 2 tbsp Banana, raisins, jam 
Whole grain rye bread 1-1.5 slices (50 g) Rye crisp bread (3 slices) 
Butter (Bregott mellan) 3 tsp  
Ham  2.5 slices (or 5-6 thin slices)  
Bell pepper 2 slices Tomato, cucumber 
  
2. Oat porridge with raisins and milk. Sandwich with butter, ham and cheese 
 
Food item  Quantity Alternative 
 
Rolled oats + water 1 dl + 2 dl Rye flakes, Buckwheat flakes 
Milk (1.5% fat) 2.5 dl   
Raisins 2.5 tbsp Banana, jam 
White bread 1-2 slices (50 g) Wheat crisp bread (3 slices)  
Butter (Bregott mellan) 4 tsp  
Ham 2.5 slices (or 5-6 thin slices)  
Cucumber 4 slices Bell pepper, tomato 
 
3. Sandwich with butter, ham, eggs and bell pepper. Banana. 
 
Food item  Quantity Alternative 
 
White bread 2 large slices (or 3 small) Wheat crisp bread (3 slices) 
Butter (Bregott mellan) 2 tsp  
Ham 2.5 slices (or 5-6 thin slices)  
Eggs 1  Boiled, fried, scrambled 
Cheese (17% fat) 2 slices  
Bell pepper 2 slices Cucumber, tomato 
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4. Sandwichs with butter, ham, cheese and tomato. Fruit yoghurt. 
 
Food item  Quantity Alternative 
 
Whole grain rye bread 2 slices (80 g) Rye crisp bread (4 slices) 
Butter (Bregott mellan) 4 tsp  
Ham 2.5 slices (or 5-6 thin slices)  
Cheese (17% fat) 1.5 slices  
Tomato 2-3 slices Cucumber, bell pepper 
Fruit yoghurt (0.5%) 2.5 dl Yoghurt + jam or raisins 
 
5. Yoghurt with muesli and banana. Wheat crisp bread with butter, ham and bell 
pepper. 
 
Food item  Quantity Alternative 
 
Yoghurt (0.5% fat) 2.5 dl  Filmjölk (0.5% fat) 
Muesli with fruit and nuts 0,75 dl  
Banana 1   
Wheat crisp bread 2 slices 1 slice white bread 
Butter (Bregott mellan) 4 tsp  
Ham 2.5 slices (or 5-6 thin slices)  
Bell pepper 2 slices Cucumber, tomato 
 
Food items 
• Whole grain rye bread refers to breads such as Lingongrova, Gott och gräddat, 
Frökusar, Skördelycka. 
 
• White bread refers to breads such as formfranska, bergis, rost/toast. 
 
• Muesli with fruit and nuts refers to cereal such as Familjemuesli, F-muesli. 
• Oat cereal (Havrefras) refers to cereal such as havrefras, Havrekuddar, Havreringar, 
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Light meal/snack 300 kcal   Meal plan for meat diet  
 
Every day choose two of the six light meal/snack alternatives below. Preferably vary your 
choice from day to day. 
• Complete the food diary and check the alternative you have chosen. 
• You do not have to eat the light meals/snacks at any particular time, and you can eat 
them at the same time or separately. 
 
 
1. Yoghurt with raisins and sunflower seeds. Fruit 
 
Food item  Quantity Alternative 
 
Yoghurt (0.5% fat) 2 dl Sour milk (0.5%) 
Raisins 3 tbsp Banana, jam 
Sunflower seeds 1.5 tbsp Pumpkin seeds, nuts 
Fruit (apple) 1 piece Pear, orange, nectarine 
 
2. Sandwich with cottage cheese and avocado. Fruit 
 
Food item  Quantity Alternative 
 
White bread 2 slices Wheat crisp bread (4 slices) 
Cottage cheese (4% fat) 2 tbsp Quark, cream cheese (4%) 
Avocado 0.25  
Fruit (apple) 1 piece Pear, orange, nectarine 
 
3. Cheese sandwich. Fruit 
 
Food item  Quantity Alternative 
 
Whole grain rye bread 2 slices Rye crisp bread (4 slices) 
Butter (Bregott mellan) 2 tsp  
Cheese (17% fat) 1.5 slices  
Fruit (apple) 1 piece Pear, orange, nectarine 
 
4. Wasa-sandwich and yoghurt drink. Fruit 
 
Food item  Quantity Alternative 
 
Wasa-sandwich 1 piece Crispbread (2 slices) + 
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Yoghurt drink 2.5 dl Fruit yoghurt (2 dl) 




5. Rusks with cheese and marmalade and fruit 
 
Food item  Quantity Alternative 
 
Whole grain rusks 1.5 – 2 pieces  
Butter (Bregott mellan) 2 tsp  
Cheese (17%) 2 slices  
Marmalade 1 tbsp  
Fruit (apple) 1 piece Pear, orange, nectarine 
 
6. Rusks with peanut butter and fruit 
 
Food item  Quantity Alternative 
 
Wheat rusks 2 pieces  
Peanut butter 4 tsp  
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Side dish - Meat diet    Meal plan  
• The side dishes consist of bread with topping and can be served along with the 
ready-made lunch or dinner dish or at any time during the day. 
• Each day, choose one of the five alternatives. Preferably vary your choice from day 
to day. 





Crisp bread (Wasa husman) 2 slices 





Crisp bread (Finn crisp) 3 slices 





Whole grain rye bread (rågkusar) 0.5 rågkuse 





Crisp bread (Wasa sport) 2 slices 





Whole grain rusks 2 pieces 
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Analysis of cardiometabolic risk factors, gut microbiota, and plasma 
metabolome 
Anthropometric measurements and assessment of quality of life  
A digital automatic sphygmomanometer (OMRON M6 AC, OMRON HEALTHCARE Co., Ltd. 
Kyoto, Japan) was used to measure blood pressure and heart rate. Blood pressure was 
measured in the right arm after five minutes of seated rest. Body height in centimeters was 
measured at baseline. Body weight in kilograms was measured at the four monitoring visits 
with the participants dressed in light clothing without shoes. BMI was calculated as body 
weight in kilograms divided by height in meters squared. At all monitoring visits, quality of life 
was assessed with the EuroQoL five-dimension questionnaire (EQ5D), which assesses 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with results 
presented on a visual analogue scale.  
Blood sampling and biochemical analyses 
Venous blood samples were collected at the four monitoring visits in evacuated plastic tubes 
(VACUETTE® TUBE, Greiner Bio-One GmbH, Kremsmunster, Austria). Upon collection, the 
tubes were gently inverted 10 times and placed on ice. Samples were centrifuged in a cooling 
system at 1560 x g for 10 min at -40°C and stored at -80°C in aliquots for analysis.  
Analyses of samples were conducted at the Clinical Chemistry Laboratory, Örebro University 
Hospital. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density 
lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured by a dry chemistry 
method using a membrane and colorimetric detection in a Vitros 5.1 FS chemistry system 
(Ortho Clinical Diagnostics and Johnson & Johnson, Stockholm, Sweden). High-sensitivity CRP 
(hs-CRP), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB) were measured with two-
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Upplands Väsby, Sweden). A six-point calibration curve and pooled samples for quality control 
were also assayed to confirm accurate measurement according to SS-EN ISO/IEC 15 189, 
STAFS 2011:33 and STAFS 2010:10 (SWEDAC). The HbA1c was measured by the gold standard 
method on a Tosho G8 High Performance Liquid Chromatography instrument (Tosho 
Bioscience, Tessenderlo, Belgium).  
We used a sandwich ELISA assay kit (Mercodia, Uppsala, Sweden) for quantitative measure of 
plasma oxidized LDL-C levels. The assay uses the specific murine monoclonal antibody mAb-
4E6 directed against the oxidized antigenic determinants on the oxidized ApoB molecule, as 
described by Holvoet et al. Fresh-frozen plasma (25 μL) was diluted in two steps to a final 
dilution of 1/6561 and combined with 100 μL of assay buffer and 25 μL of each calibrator. 
Control and diluted samples were added to appropriate wells on the plate. Plates were 
incubated in a plate shaker (700–900 rpm) for 2 hours at 20ºC and washed six times with 700 
μL wash buffer per well using an automatic plate washer. The plates were inverted and 
tapped against absorbent tissue, and 100 μL of enzyme conjugate was added to each well. 
Following a second incubation for 1 h on a plate shaker, the plates were washed, and 200 μL 
of substrate tetramethylbenzidine was added. Finally, the plates were incubated for 15 min 
on the bench, 50 μL of a solution to stop the reaction was added, and the optical density was 
measured spectrophotometrically at 450 nm. Two commercially available controls were 
included on each plate (n=3) for internal quality control. The intra-assay coefficient of 
variation for oxidized LDL-C concentration was <10% for 95.7% of samples.  
16S rRNA gene sequencing for gut microbiome 
Fecal samples were collected in sterile stool tubes on the day prior to each baseline/follow-
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sample by repeated bead-beating and was subjected to 16S rRNA gene sequencing in an 
Illumina Miseq instrument (Illumina, San Diego, California, USA) using the 515F and 806R 
primers and the V2 kit (2 × 250 bp paired-end reads) (Illumina).  
Illumina reads were merged using Usearch v. 11 64-bit allowing for up to 30 mismatches in 
the alignment of the paired-end reads, while discarding reads with a merged length greater 
than 270 bp and fewer than 230 bp. The merged reads were quality-filtered based on 
expected errors, removing reads above the threshold of 1.0. The merged reads were 
converted to zero-radius operational taxonomic units (ZOTU) by compiling the sequences into 
sets of unique reads and performing error-correction using the UNOISE3 algorithm, discarding 
sequences with fewer than four reads. The ZOTUs were assigned taxonomy using DADA2’s 
assign Taxonomy (minBoot = 80) and were assigned species, using the properly formatted 
version of the Silva v. 132 database. A phylogenetic tree of the sequence attributed to each 
ZOTU was created by aligning the reads using MAFFT v. 7.407 and FastTree v. 2.1.10. The 
process produced 3,126 ZOTUs after removing dropouts, comprising 8,344,360 reads from 
102 samples. The OTU-table was subjected to filtering based on abundance, and ZOTUs below 
0.002% of total reads in the table were discarded,13 resulting in 1,264 amplicon sequence 
variants in 102 samples (8,253,321 reads). Data were rarefied to the minimum sample 
sequence depth (56,103 reads) to reduce the effect of sequencing depth.  
Measurement of fecal short chain fatty acids and branched chain fatty acids 
Fecal concentrations of the short chain fatty acids (SCFA) acetate, propionate, and butyrate 
and branched chain fatty acids (BCFA) isobutyrate and isovalerate, as well as succinate and 
lactate, were determined using gas chromatograph-mass spectrometry (Agilent 
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transferred to a 16 x 125 mm glass tube fitted with a screw cap, and a volume of 100 µL of 
internal standard stock solution [(1-13C)acetate, (2H6)propionate 1 M, (13C4)butyrate 0.5 M, 
(1-13C1)isobutyrate, and (1-13C)isovalerate 0.1 M] was added. Prior to extraction, samples 
were freeze-dried at -50ºC for 3 h. After acidification with 50 µL of 37% HCl, the organic acids 
were extracted twice in 2 mL of diethyl ether. A 500 µL aliquot of the extracted sample was 
mixed with 50 µL of N-tert-butyldimethylsilyl-N-methyltrifluoracetamide (Sigma) at 20ºC. One 
µl of the derived material was injected into a gas chromatograph (Agilent Technologies 7890 
A) coupled to a mass spectrometer detector (Agilent Technologies 5975 C). Temperature was 
increased in a linear gradient consisting of initial temperature of 65ºC for 6 min, increase to 
260 ºC at 15ºC min-1, and increase to and held at 280ºC for 5 min. The injector and transfer 
line temperatures were 250ºC. Quantitation was completed in ion-monitoring acquisition 
mode by comparison to labelled internal standards, with the m/z ratios 117 (acetic acid), 131 
(propionic acid), 145 (butyric acid), 146 (isobutyric acid), 159 (isovaleric acid), 121 [(2H2)- and 
(1-13C)acetate], 136 [(2H5)propionate], 146 [(1-13C1)isobutyrate], 149 [(13C4) butyrate], 
160 [(1-13C)isovalerate]. 
Plasma metabolome analysis 
Plasma samples were de-proteinized using ultracentrifugation and analyzed by high 
performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-
qTOF-MS/MS, Agilent qTOF 6520) (Agilent Technologies). Reverse-phase chromatography 
was applied using an ACQUITY UPLC HSS T3 Column (130Å, 1.8 μm, 2.1 mm×100 mm (Waters) 
in positive (ESI+) and negative electrospray ionization (ESI-) modes.  
The mobile phase delivered at 400 µL/min consisted of eluent A (MilliQ purified water) 
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Riedel-de Haen), both containing 0.04% (vol:vol) formic acid. The ESI source was operated 
under the following conditions: gas (nitrogen) temperature 175℃ and dry gas flow 10 L/min, 
nebulizer pressure 45 PSI, capillary voltage 3500 V, fragmenter 125 V, and a skimmer of 65V. 
For data acquisition, a 2-GHz extended dynamic range mode was used, with the instrument 
set to acquire data over the m/z range 50–1700. Data were collected in centroid mode at an 
acquisition rate of 1.67 spectra/s with an abundance threshold of 200 counts. Continuous 
mass axis calibration was performed in an infusion solution throughout the runs by 
monitoring reference ions m/z 121.050873 and m/z 922.009798 for positive mode and m/z 
112.988900 and 966.000725 for negative mode.  
Plasma samples were analyzed in two batches. Within-individual samples were analyzed in 
the same batch, with full within-batch randomization. The stability and functionality of the 
system were monitored throughout the instrumental analyses using pooled plasma samples 
as quality control. Data acquisition used MassHunter Acquisition software (Agilent 
Technologies). 
Raw data acquired in each analytical batch were converted to mzXL format, and 
deconvolution was performed with the open source R package “XCMS.” Key parameters of 
XCMS including peak detection, alignment, and correspondence were optimized using the R 
package “IPO” to increase the reliability and stability of processed metabolomics data. The 
number of obtained metabolite features (mass spectral peak, a molecular entity with a unique 
mass-to-charge ratio and retention time as measured by LC-MS instrument) with ESI+ and ESI- 
was 1645 and 1363, respectively. The within- and between- batch measurement errors due 
to shifts in retention time, mass-to-charge ratio (m/z), and intensity of metabolite features 




 http://ahajournals.org by on O
ctober 13, 2020
metabolite features passing the quality control tests (CV<0.3) in both batches were 
considered qualified features and were subjected to statistical analysis. In total, 840 and 982 
features from the ESI+ and ESI- were retained after stringent normalization procedures. 
Plasma trimethylamine N-oxide (TMAO), choline, carnitine, and acetyl-carnitine were 
measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) analyzed on an  
Exion UHPLC coupled to a QTRAP 6500+ MS/MS system, both from AB Sciex LLC (Framingham, 
USA).  Plasma (50 L) was thoroughly mixed with methanol (150 L) and internal standard 
solution (50 L) containing d9-TMAO, d11-choline, and d9-carnitine was centrifuged at 15 000 
x g at 5°C for 10 min and supernatants collected on vials for analysis. Calibration curves were 
obtained from a stock solution containing all compounds. The separation used a Waters BEH 
Amide column (100 x2.1 mm, 1.7 m) at 35°C with flow of 0.75 mL/min. The gradient was 0% 
B 0–1.3 min to 80% B at 4.5 min (B was 10mM ammonium formate in acetonitrile and A 10 
mM ammonium formate in water, pH 3, injection volume 0.3 L). The analytes were detected 
using positive electrospray ionization. Transitions were TMAO 76.1–>58.2, choline 105.1–
>61, L-carnitine 163.1–>116.9, acetyl-carnitine 204.1–>85.1.  
Statistical analysis 
All analyses were performed in R v. 3.5.1. (R Foundation for Statistical Computing, Vienna, 
Austria). 
Packages Purpose References and open source 
tutorials 
XCMS Metabolomics data processing https://bioconductor.org/packa
ges/release/bioc/vignettes/xcms
/inst/doc/xcms.html  
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mixOmics Supervised modelling http://mixomics.org/  
batchCorr Metabolomics data normalization https://www.ncbi.nlm.nih.gov/p
ubmed/27746707  
MUVR Supervised modelling https://academic.oup.com/bioin
formatics/article/35/6/972/508
5367  
vegan Microbiota data analyses http://cc.oulu.fi/~jarioksa/opetu
s/metodi/vegantutor.pdf  
ggplot2 Results visualization and interpretation https://cran.r-
project.org/web/packages/ggplo
t2/ggplot2.pdf  
phyloseq Microbiome census data analysis https://joey711.github.io/phylos
eq/  
Picante Microbiota diversity calculation https://cran.r-
project.org/web/packages/pican
te/vignettes/picante-intro.pdf  
Hmisc Descriptive statistics http://math.furman.edu/~dcs/c
ourses/math47/R/library/Hmisc
/html/Overview.html  
lme4 Generalized linear mixed model https://github.com/lme4/lme4/ 
Descriptive statistics of anthropometric measurements and clinical markers 
Normality of distribution of the variables and residuals was visualized using a histogram and 
tested using the Shapiro-Wilks test. Missing values were imputed in an intention-to-treat 
analysis using the last observation carried forward method for the participants (n=2) who 
were randomized but did not receive intervention and for the participants that dropped out 
after the first intervention (n=2). A two-sided P value <0.05 was considered significant.  
To investigate whether a VD could alter cardiovascular risk factor in IHD patients, the number 
of participants exhibiting guideline target values of clinical markers before and after 
intervention was calculated. Cut-off values of clinical markers routinely measured after a 
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prevention in clinical practice: LDL-C <1.8 mmol/L, systolic blood pressure <130 mmHg or 
diastolic blood pressure <80 mmHg, and BMI <25 kg/m2.  
Descriptive statistics of gut microbiota  
The graphic representations and statistical analyses of microbiota were performed using 
phyloseq v. 1.26 and ggplot2 v. 3. To investigate bacterial richness and phylogenetic diversity 
within samples, Faith’s Phylogentic Diversity and richness were calculated using Picante v. 1.7, 
and pairwise comparisons of the diets were implemented using a paired Wilcoxon test. To 
compare gut bacterial patterns of subjects consuming the same and different diets, Bray-
Curtis dissimilarity, Weighted UniFrac, and Unweighted UniFrac were calculated using Vegan 
v. 2.5-4. Principal Coordinates Analysis (PcoA) and a permutation ANOVA (Adonis) was 
performed to assess differences in the microbiome associated with the diets. A differential 
abundance analysis of the OTUs was conducted on a subset of the OTUs existing in more than 
20 samples using a pairwise paired Wilcoxon test. 
Multilevel-predictive modelling for gut microbiota and plasma metabolome 
To identify microbial taxa and plasma metabolites discriminating the VD from the MD, 
random-forest-modeling-based multilevel data analyses (ML-RF) were applied using the R 
package ‘MUVR’ for the pair-wise comparison of the ZOTUs or metabolites in subjects 
consuming the VD and MD. A multilevel analysis deals with dependent data structures and 
has been successfully used to exploit the differences specific to diet in cross-over human 
nutrition intervention studies. In this ML-RF algorithm, random forest is applied on the within-
subject variation matrix, i.e. the relative abundance of microbial genera observed in the two 
interventions as independent variables. The model is further incorporated into repeated 
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improve prediction accuracy, and to identify the most informative features of treatments. 
Permutation analysis was performed to test overall model validity and degree of overfitting 
by calculating the cumulative probability of actual model misclassification within a t-
distributed H0 population (n=100).  
We applied generalized linear mixed modelling to compare VD vs. MD with respect to each of 
the selected discriminative ZOTUs and metabolites using the R package ‘lme4.’ Fixed factors 
included diet, sequence of intervention allocation, and baseline values as covariates and 
subject as random factor. This analysis was also applied on fecal concentrations of SCFAs. 
Within-treatment effects were similarly investigated with respect to relative abundance of 
microbial taxa at baseline and following intervention. 
Baseline gut microbiota and plasma metabolites associated with response to diet with 
respect to clinical outcomes  
We investigated whether gut microbiota configuration or plasma metabolome at baseline 
was associated with the effects a VD on metabolic risk factors including oxidized LDL-C, LDL-
C, TC, and BMI. Random forest modelling (R package ‘MUVR’) was used to identify a panel of 
baseline microbial genera and plasma metabolites that discriminated subjects who showed 
lower metabolic risk factors after VD than seen with MD (responders) from those in whom 
VD did not reduce improve metabolic risk factors compared to MD (non-responders). 
Energy-adjusted meal plans 
The meal plan was personally adapted according to individual energy requirements and was 
energy- and macronutrient balanced. A research dietitian calculated the energy requirement 
for each subject by multiplying the Basal Metabolic Rate (BMR) with the Physical Activity Level 
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to Nordic Nutrition Recommendations based on data of physical activity stated by participants 
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Table S1. Details of ready-made meat meals. 











1. 1. Mon Lunch Dafgårds – Chicken Quiche 240 592.8 22.32 38.4 38.4 2.88 23.28 
  Dinner Dafgårds - Meatballs & Red Peppers 400 480 24 24 36 12 10.8 
  Total     1072.8 46.32 62.4 74.4 14.88 34.08 
 2. Tue Lunch Dafgårds - Spaghetti Bolognese 400 480 24.4 16.4 64 5.6 7.6 
  Dinner Dafgårds – Cheese and Ham Quiche 240 602.4 21.36 40.8 36 1.68 24 
  Total    1082.4 45.76 57.2 100 7.28 31.6 
 3. Wed Lunch Dafgårds – Beef Stew 400 364 20 13.2 35.6 4.8 5.2 
  Dinner Dafgårds – Kebab 400 672 20.4 44 56 7.2 16 
  Total    1036 40.4 57.2 91.6 12 21.2 
 4. Thur Lunch Dafgårds – Greek Beef 380 456 18.24 23.94 41.8 6.84 9.5 
  Dinner Dafgårds – Hash  380 646 14.44 37.62 60.8 4.94 11.78 
  Total    1102 32.68 61.56 102.6 11.78 21.28 
 5. Fri Lunch Dafgårds – Oven roasted chicken  420 504 30.66 13.02 63 4.2 5.88 
  Dinner Dafgårds – Taco plate 390 565.5 19.11 26.52 58.5 3.9 12.09 
  Total    1069.5 49.77 39.54 121.5 8.1 17.97 
 6. Sat Lunch Dafgårds – Fried Falun sausage 
 
400 504 10.4 38.4 48 3.2 13.2 
  Dinner Dafgårds – Fried Pork Loin 420 558.6 22.68 26.04 54.6 7.14 8.82 
  Total    1062.6 33.08 64.44 102.6 10.34 22.02 
 7. Sun Lunch Dafgårds – Chicken Lasagna 420 504 29.4 13.86 67.2 2.52 8.4 
  Dinner Dafgårds – Angus burger 380 558.6 17.1 36.86 38 4.56 14.82 
  Total    1062.6 46.5 50.72 105.2 7.08 23.22 
           
2. 8. Mon Lunch Dafgårds – Farmer burger 400 640 20.4 38 52 6.8 11.2 
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  Total    1120 44.8 54.4 116 12.4 18.8 
 9. Tue Lunch Dafgårds - Greek Beef 380 456 18.24 23.94 41.8 6.84 9.5 
  Dinner Dafgårds – Chicken schnitzel 390 624 23.4 29.25 66.3 7.02 7.02 
  Total    1080 41.64 53.19 108.1 13.86 16.52 
 10. Wed Lunch Dafgårds - Cheese and Ham Quiche 240 602.4 21.36 40.8 36 1.68 24 
  Dinner Dafgårds - Meatballs & Red Peppers 400 480 24 24 36 12 10.8 
  Total    1082.4 45.36 64.8 72 13.68 34.8 
 11. Thur Lunch Dafgårds - Fried Falun sausage 400 504 10.4 38.4 48 3.2 13.2 
  Dinner Dafgårds - Chicken Quiche 240 592.8 22.32 38.4 38.4 2.88 23.28 
  Total    1096.8 32.72 76.8 86.4 6.08 36.48 
 12. Fri Lunch Dafgårds - Beef Stew 400 364 20 13.2 35.6 4.8 5.2 
  Dinner Dafgårds – Italian style veal burgers 400 660 24.4 32.4 64 6.4 9.2 
  Total    1024 44.4 45.6 99.6 11.2 14.4 
 13. Sat Lunch Dafgårds - Oven roasted chicken 420 504 30.66 13.02 63 4.2 5.88 
  Dinner Dafgårds – Taco plate 390 565.5 19.11 26.52 58.5 3.9 12.09 
  Total    1069.5 49.77 39.54 121.5 8.1 17.97 
 14. Sun Lunch Dafgårds - Cabbage pudding 400 352 13.6 22.8 37.6 6 5.6 
  Dinner Dafgårds – Kebab 400 672 20.4 44 56 7.2 16 
  Total    1024 34 66.8 93.6 13.2 21.6 
           
3. 15. Mon Lunch Dafgårds – Angus burger 380 558.6 17.1 36.86 38 4.56 14.82 
  Dinner Dafgårds - Chicken Lasagna 420 504 29.4 13.86 67.2 2.52 8.4 
  Total    1062.6 46.5 50.72 105.2 7.08 23.22 
 16. Tue Lunch Dafgårds - Farmer burger 400 640 20.4 38 52 6.8 11.2 
  Dinner Dafgårds – Pork stew 380 418 20.14 9.88 57 3.04 4.56 
  Total    1058 40.54 47.88 109 9.84 15.76 
 17. Wed Lunch Dafgårds - Fried Pork Loin 420 558.6 22.68 26.04 54.6 7.14 8.82 
  Dinner Dafgårds - Oven roasted chicken  420 504 30.66 13.02 63 4.2 5.88 
  Total    1062.6 53.34 39.06 117.6 11.34 14.7 
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  Dinner Dafgårds - Italian style veal burgers 400 660 24.4 32.4 64 6.4 9.2 
  Total    1012 38 55.2 101.6 12.4 14.8 
 19. Fri Lunch Dafgårds - Hash  380 646 14.44 37.62 60.8 4.94 11.78 
  Dinner Dafgårds - Greek Beef 380 456 18.24 23.94 41.8 6.84 9.5 
  Total    1102 32.68 61.56 102.6 11.78 21.28 
 20. Sat Lunch Dafgårds – Kebab 400 672 20.4 44 56 7.2 16 
  Dinner Dafgårds - Meatballs & Red Peppers 400 480 24 24 36 12 10.8 
  Total    1152 44.4 68 92 19.2 26.8 
 21. Sun Lunch Dafgårds - Spaghetti Bolognese 400 480 24.4 16.4 64 5.6 7.6 
  Dinner Dafgårds - Chicken schnitzel 390 624 23.4 29.25 66.3 7.02 7.02 
  Total    1104 47.8 45.65 130.3 12.62 14.62 
           
4. 22. Mon Lunch Dafgårds - Chicken Quiche 240 592.8 22.32 38.4 38.4 2.88 23.28 
  Dinner Dafgårds - Angus burger 380 558.6 17.1 36.86 38 4.56 14.82 
  Total    1151.4 39.4 75.26 76.4 7.44 38.1 
 23. Tue Lunch Dafgårds - Cabbage pudding 400 352 13.6 22.8 37.6 6 5.6 
  Dinner Dafgårds - Italian style veal burgers 400 660 24.4 32.4 64 6.4 9.2 
  Total    1012 38 55.2 101.6 12.4 14.8 
 24. Wed Lunch Dafgårds - Cheese and Ham Quiche 240 602.4 21.36 40.8 36 1.68 24 
  Dinner Dafgårds – Pork Stew 380 418 20.14 9.88 57 3.04 4.56 
  Total    1020.4 41.5 50.68 93 4.72 28.56 
 25. Thur Lunch Dafgårds - Beef Stew 400 364 20 13.2 35.6 4.8 5.2 
  Dinner Dafgårds - Hash  380 646 14.44 37.62 60.8 4.94 11.78 
  Total    1010 34.44 50.82 96.4 9.74 16.98 
 26. Fri Lunch Dafgårds - Fried Falun sausage 400 504 10.4 38.4 48 3.2 13.2 
  Dinner Dafgårds - Chicken schnitzel 390 624 23.4 29.25 66.3 7.02 7.02 
  Total    1128 33.8 67.65 114.3 10.22 20.22 
 27. Sat Lunch Dafgårds - Farmer burger  400 640 20.4 38 52 6.8 11.2 
  Dinner Dafgårds - Chicken Lasagna 420 504 29.4 13.86 67.2 2.52 8.4 
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 28. Sun Lunch Dafgårds - Taco plate 390 565.5 19.11 26.52 58.5 3.9 12.09 
  Dinner Dafgårds - Fried Pork Loin 420 558.6 22.68 26.04 54.6 7.14 8.82 
  Total    1124.1 41.79 52.56 113.1 11.04 20.91 
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Table S2. Details of ready-made vegetarian meals. 










1. 1. Mon Lunch Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
400 576 20.4 24 66 7.6 4 
  Dinner Dafgårds - Cheese & Broccoli pie 220 484 19.8 28.6 37.4 2.64 14.52 
  Total    1060 40.2 52.6 103.4 10.24 18.52 
 2. Tue Lunch Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Dinner Dafgårds – Broccoli balls with quinoa 
and pepper sauce 
400 448 27.2 15.2 45.6 10.4 5.6 
  Total    1009.6 46.4 53.6 81.6 13.04 28.64 
 3. Wed Lunch Dafgårds – Vegetable pie with 
wholegrain crust 
220 440 14.96 21.56 41.8 7.04 9.9 
  Dinner Dafgårds - Falafel 400 560 20.4 25.2 64 11.2 3.6 
  Total    1000 35.36 46.76 105.8 18.24 13.5 
 4. Thur Lunch Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
420 508.2 19.32 16.8 65.52 7.14 4.62 
  Dinner Dafgårds - Indian lentil Stew  400 516 23.2 20.4 56 11.6 11.2 
  Total    1024.2 42.52 37.2 121.52 18.74 15.82 
 5. Fri Lunch Dafgårds - Cheese & Broccoli pie 220 484 19.8 28.6 37.4 2.64 14.52 
  Dinner Dafgårds – Veggie burger 400 516 19.2 26.4 48 9.6 4.4 
  Total    1000 39 55 85.4 12.24 18.92 
 6. Sat Lunch Dafgårds - Kale steak 380 338.2 13.68 6.84 53.2 9.12 0.76 
  Dinner Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Total    899.8 32.88 45.24 89.2 11.76 23.8 
 7. Sun Lunch Dafgårds – Broccoli balls with quinoa 
and pepper sauce 
400 448 27.2 15.2 45.6 10.4 5.6 
  Dinner Dafgårds - Mexican bean steak 390 534.3 14.04 24.96 66.3 4.68 8.97 
  Total    982.3 41.24 40.16 111.9 15.08 14.57 
2. 8. Mon Lunch Dafgårds - Cheese & Broccoli pie 220 484 19.8 28.6 37.4 2.64 14.52 
  Dinner Dafgårds - Falafel 400 560 20.4 25.2 64 11.2 3.6 




 http://ahajournals.org by on O
ctober 13, 2020
 9. Tue Lunch Dafgårds – Vegetable pie with 
wholegrain crust 
220 440 14.96 21.56 41.8 7.04 9.9 
  Dinner Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
400 576 20.4 24 66 7.6 4 
  Total    1016 35.36 45.56 107.8 14.64 13.9 
 10. 
Wed 
Lunch Dafgårds – Broccoli balls with quinoa 
and pepper sauce 
400 448 27.2 15.2 45.6 10.4 5.6 
  Dinner Dafgårds - Mexican bean steak 390 534.3 14.04 24.96 66.3 4.68 8.97 
  Total    982.3 41.24 40.16 111.9 15.08 14.57 
 11. 
Thur 
Lunch Dafgårds - Indian lentil Stew  400 516 23.2 20.4 56 11.6 11.2 
  Dinner Dafgårds – Veggie burger 400 516 19.2 26.4 48 9.6 4.4 
  Total    1032 42.4 46.8 104 21.2 15.6 
 12. Fri Lunch Dafgårds - Kale steak 380 338.2 13.68 6.84 53.2 9.12 0.76 
  Dinner Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Total    899.8 32.88 45.24 89.2 11.76 23.8 
 13. Sat Lunch Dafgårds – Sun-dried tomato/pea 
steak with vegetables 
420 508.2 19.32 16.8 65.52 7.14 4.62 
  Dinner Dafgårds - Mexican bean steak 390 534.3 14.04 24.96 66.3 4.68 8.97 
  Total    1042.5 33.36 41.76 131.82 11.82 13.59 
 14. Sun Lunch Dafgårds - Falafel  400 560 20.4 25.2 64 11.2 3.6 
  Dinner Dafgårds - Indian lentil Stew  400 516 23.2 20.4 56 11.6 11.2 
  Total    1076 43.6 45.6 120 22.8 14.8 
3. 15. 
Mon 
Lunch Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
400 576 20.4 24 66 7.6 4 
  Dinner Dafgårds - Kale steak 380 338.2 13.68 6.84 53.2 9.12 0.76 
  Total    914.2 34.08 30.84 119.2 16.72 4.76 
 16. Tue Lunch Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Dinner Dafgårds – Broccoli balls with quinoa 
and pepper sauce 
400 448 27.2 15.2 45.6 10.4 5.6 
  Total    1009.6 46.4 53.6 81.6 13.04 28.64 
 17. 
Wed 
Lunch Dafgårds - Sun-dried tomato/pea 
steak with vegetables 
420 508.2 19.32 16.8 65.52 7.14 4.62 
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  Total    1068.2 39.72 42 129.52 18.34 8.22 
 18. 
Thur 
Lunch Dafgårds – Veggie burger 400 516 19.2 26.4 48 9.6 4.4 
  Dinner Dafgårds - Cheese & Broccoli pie 220 484 19.8 28.6 37.4 2.64 14.52 
  Total    1000 39 55 85.4 12.24 18.92 
 19. Fri Lunch Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Dinner Dafgårds - Indian lentil Stew  400 516 23.2 20.4 56 11.6 11.2 
  Total    1077.6 42.4 58.8 92 14.24 34.24 
 20. Sat Lunch Dafgårds - Kale steak 380 338.2 13.68 6.84 53.2 9.12 0.76 
  Dinner Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
400 576 20.4 24 66 7.6 4 
  Total    914.2 34.08 30.84 119.2 16.72 4.76 
 21. Sun Lunch Dafgårds – Vegetable pie with 
wholegrain crust 
220 440 14.96 21.56 41.8 7.04 9.9 
  Dinner Dafgårds - Mexican bean steak 390 534.3 14.04 24.96 66.3 4.68 8.97 
  Total    974.3 29 46.52 108.1 11.72 18.87 
4. 22. 
Mon 
Lunch Dafgårds - Veggieburger 400 516 19.2 26.4 48 9.6 4.4 
  Dinner Dafgårds - Sun-dried tomato/pea 
steak with vegetables 
420 508.2 19.32 16.8 65.52 7.14 4.62 
  Total    1024.2 38.52 43.2 113.52 16.74 9.02 
 23. Tus Lunch Dafgårds - Falafel 400 560 20.4 25.2 64 11.2 3.6 
  Dinner Dafgårds – Vegetable pie with 
wholegrain crust 
220 440 14.96 21.56 41.8 7.04 9.9 
  Total    1000 35.36 46.76 105.8 18.24 13.5 
 24. 
Wed 
Lunch Dafgårds - Pea/Sun-dried tomato 
steak with pasta 
400 576 20.4 24 66 7.6 4 
  Dinner Dafgårds - Kale steak 380 338.2 13.68 6.84 53.2 9.12 0.76 
  Total    914.2 34.08 30.84 119.2 16.72 4.76 
 25. 
Thur 
Lunch Dafgårds – Broccoli balls with quinoa 
and pepper sauce 
400 448 27.2 15.2 45.6 10.4 5.6 
  Dinner Dafgårds - Asparagus pie 240 561.6 19.2 38.4 36 2.64 23.04 
  Total    1009.6 46.4 53.6 81.6 13.04 28.64 
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  Dinner Dafgårds – Veggie burger 400 516 19.2 26.4 48 9.6 4.4 
  Total    1000 39 55 85.4 12.24 18.92 
 27. Sat Lunch Dafgårds - Sun-dried tomato/pea 
steak with vegetables 
420 508.2 19.32 16.8 65.52 7.14 4.62 
  Dinner Dafgårds - Indian lentil Stew 400 516 23.2 20.4 56 11.6 11.2 
  Total    1024.2 42.52 37.2 121.52 18.74 15.82 
 28. Sun Lunch Dafgårds – Vegetable pie with 
wholegrain crust 
220 440 14.96 21.56 41.8 7.04 9.9 
  Dinner Dafgårds - Mexican bean steak 390 534.3 14.04 24.96 66.3 4.68 8.97 
  Total    974.3 29 46.52 108.1 11.72 18.87 
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Table S3. Dietary intake before and during the two intervention periods, VD (vegetarian diet) and MD (meat diet), based on 3-day weighed 
food records+.  
 Pre VD VD Pre MD MD 
















 mean median [IQR] mean median [IQR] mean median [IQR] mean median [IQR] 










































































♦  Pre VD/MD: Reported dietary intake before VD or MD intervention period (at baseline or end of washout) ♦ VD/MD: Reported dietary intake of VD/MD  ♦     
♦  IQR: Interquartile range ♦ Pooled data: Multiple imputation was used for missing values ♦ Wilcoxon Rank Sum test was used for all comparisons ♦ p <0.05 was considered significant  ♦ 
* Borderline significant difference in pooled data (Imputation number/p-values: 1/0.006, 2/0.04, 3/0.01, 4/0.03, 5/0.07) of protein intake of Pre VD and VD   
** Significant difference in pooled data (Imputation number/p-values: 1/P=0.000, 2/P=0.000, 3/P=0.000, 4/P=0.001, 5/P=0.000) of protein intake between Pre MD and 
MD. *** Significant difference in original data (p=0.046) of protein intake between Pre MD and MD.  
**** Significant difference in pooled data (Imputation number/p-values: 1/P=0.008, 2/P=0.02, 3/P=0.02, 4/P=0.002, 5/P=0.01) between fiber intake of VD and MD. 
+three-day weighed food information was collected four times during the study: during the week before baseline, the last week of VD, the last week of the washout 
period, and the last week of MD. 58% (18/31) completed all four registrations. Food records with daily total energy intake:basal metabolic rate <1 were considered as 
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Table S4. Adherence to the intervention diets. 















































♦ Pooled data: Multiple imputation was used for missing values ♦ Wilcoxon signed rank sum test was used for analysis ♦ 
*Significant difference in overall adherence of the pooled data (Imputation number/P-values: 1/P=0.01, 
2/P=0.02, 3/P=0.01, 4/P=0.02, 5/P=0.01) in snacks of VD and MD. 
**Borderline significant difference in overall adherence (Imputation number/p-values: 1/P=0.05, 2/P=0.03, 
3/P=0.03, 4/P=0.04, 5/P=0.1) between VD and MD. 
VD (vegetarian diet) and MD (meat diet), in mean percentage (%) adherence the prescribed diet, calculated 
from the self-reported study diaries. To assess the adherence to the intervention diets, the participants were 
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Table S5. Participants exhibiting guideline target values of clinical markers/dietary 
intervention. 






Post VD vs.  
Post MD 
LDL-C <1.8 mmol/L, 
n (%) 
22 (71.0) 27 (87.1) 22 (71.0) 24 (77.4) -3 (9.7) 
BMI <25 kg/m2, n 
(%) 
4 (12.9) 6 (19.4) 5 (16.1) 4 (12.9) -2 (6.5) 
Diastolic Bp <80 
mmHg, n (%) 
9 (29.0) 8 (25.8) 7 (22.6) 6 (19.4) -2 (6.5) 
Systolic Bp <130 
mmHg, n (%) 
11 (35.5) 14 (45.2) 9 (29.0) 12 (38.7) -2 (6.5) 
BMI, Body-mass index; Bp, Blood pressure; LDL-C, Low-density lipoprotein cholesterol; MD, 
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Table S6. Assessed quality of life relative to dietary intervention. 








Post VD vs. 
Post MD 












-No problems, n (%) 27 (87) 27 (87) 28 (90) 27 (87) 0 (0) 
-Some problems, n (%) 4 (13) 4 (13) 3 (10) 4 (13) 0 (0) 
-Extreme problems, n (%) 0 (0) 0(0) 0 (0) 0 (0) 0 (0) 
Self-care 
-No problems, n (%) 31 (100) 31(100) 31 (100) 31(100) 0 (0) 
-Some problems, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
-Extreme problems, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Usual-activities 
-No problems, n (%) 30 (97) 31 (100) 31(100) 31(100) 0 (0) 
-Some problems, n (%) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 
-Extreme problems, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Pain/discomfort 
-No problems, n (%) 17 (55) 17 (55) 16 (52) 17 (55) 0 (0) 
-Some problems, n (%) 14 (45) 14 (45) 14 (45) 14 (45) 0 (0) 
-Extreme problems, n (%) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 
Anxiety/depression 
-No problems, n (%) 24 (77) 26 (84) 24 (77) 25 (81) 1 (3.2) 
-Some problems, n (%) 7 (23) 5 (16) 7 (23) 6 (19) -1 (-3.2) 
-Extreme problems, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
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Table S7. Effect of dietary intervention on clinical parameters according to on-treatment 
analysis. 














































































































































































Data are presented as mean (95% C.I) or as geometric mean [95 % C.I]. Within-group change 
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#Differences in clinical parameters between vegetarian diet (VD) and meat diet (MD) were 
examined using linear mixed-effects models adjusted for sequence of randomisation and 
period of interventions. Apo: Apolipoprotein, Bp; Blood pressure, Bpm; beats per minute, 
HbA1c; Glycated haemoglobin; HDL-C; High-density lipoprotein cholesterol, Hr; Heart rate, 
Hs-CRP; High-sensitive c-reactive protein, Kg; Kilograms, LDL-C; Low-density lipoprotein 
cholesterol, mmHg; millimetres of mercury, MD: meat diet; TC; Total cholesterol, TG; 
Triglycerides; VD: vegetarian diet. To convert cholesterol markers to millimoles per liter, 
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Table S8. Gut bacteria genera post-dietary intervention. 
Phylum Class Family Genus Post-MD* Post-VD* SEM p 
Firmicutes Clostridia Lachnospiraceae Shuttleworthia # 0.56 7.02 1.24 0.00 
Firmicutes Clostridia Ruminococcaceae DTU089# 15.41 7.17 1.99 0.00 
Firmicutes Clostridia Ruminococcaceae Ruminiclostridium_5# 390.12 200.71 38.41 0.00 
Firmicutes Clostridia Clostridiaceae_1 Clostridium_sensu_stricto_1# 567.77 353.04 106.8
6 
0.00 
Firmicutes Clostridia Ruminococcaceae Negativibacillus# 24.94 13.05 3.85 0.00 
Firmicutes Clostridia Ruminococcaceae Anaerofilum# 4.33 2.01 0.68 0.01 
Proteobacteria Gammaproteobacteria Burkholderiaceae Parasutterella# 46.45 33.73 4.43 0.03 
Firmicutes Clostridia Ruminococcaceae Oscillospira# 16.38 11.52 2.38 0.04 
Firmicutes Clostridia Lachnospiraceae Fusicatenibacter# 743.99 898.35 90.56 0.04 
Cyanobacteria Melainabacteria NA NA# 19.44 8.29 4.43 0.04 
Bacteroidetes Bacteroidia Tannerellaceae Parabacteroides# 309.61 216.68 33.51 0.05 
Verrucomicrobia Verrucomicrobiae Akkermansiaceae Akkermansia# 426.26 811.53 203.6
3 
0.04 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_FCS020_group# 98.89 85.22 6.00 0.06 
Actinobacteria Coriobacteriia Eggerthellaceae Adlercreutzia# 25.77 17.66 2.90 0.06 
Firmicutes Erysipelotrichia Erysipelotrichaceae NA# 13.85 7.14 3.82 0.06 
Firmicutes Clostridia Clostridiales_vadinBB60_group NA# 25.56 16.79 4.71 0.07 
Bacteroidetes Bacteroidia NA NA# 0.98 2.15 0.43 0.07 
Actinobacteria Coriobacteriia Eggerthellaceae DNF00809# 4.53 7.36 1.11 0.08 
Tenericutes Mollicutes NA NA# 15.37 9.09 3.36 0.08 
Firmicutes Clostridia Ruminococcaceae Butyricicoccus# 179.12 220.22 27.20 0.08 
Actinobacteria Coriobacteriia Eggerthellaceae Senegalimassilia# 39.67 29.54 5.61 0.08 
Tenericutes Mollicutes NA NA# 23.83 60.39 16.18 0.08 
Euryarchaeota Methanobacteria Methanobacteriaceae Methanobrevibacter# 110.14 162.22 34.79 0.09 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-005# 834.72 677.37 98.87 0.09 
Firmicutes Clostridia Peptostreptococcaceae Intestinibacter# 338.76 239.26 49.91 0.09 
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Firmicutes Negativicutes Veillonellaceae Dialister# 618.60 468.50 82.27 0.10 
Firmicutes Bacilli Lactobacillaceae Lactobacillus# 33.00 93.27 29.36 0.10 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-007# 6.70 5.09 1.11 0.14 
Firmicutes Clostridia Lachnospiraceae Marvinbryantia# 121.84 185.73 33.03 0.15 
Firmicutes Clostridia Ruminococcaceae Angelakisella# 12.38 9.88 1.69 0.17 
Firmicutes Clostridia Family_XIII Family_XIII_UCG-001# 20.74 15.66 2.97 0.17 
Bacteroidetes Bacteroidia Rikenellaceae Alistipes# 566.34 484.11 58.10 0.20 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_NK4A214_group# 301.27 382.87 66.64 0.27 
Proteobacteria Gammaproteobacteria Enterobacteriaceae Escherichia/Shigella# 125.64 292.68 106.6
5 
0.28 
Actinobacteria Coriobacteriia Eggerthellaceae Eggerthella# 7.20 1.60 4.47 0.29 
Firmicutes Clostridia Lachnospiraceae Butyrivibrio# 321.91 107.98 140.7
8 
0.29 
Firmicutes Clostridia Ruminococcaceae Hydrogenoanaerobacterium# 3.32 3.89 1.14 0.39 
Firmicutes Clostridia Lachnospiraceae UC5-1-2E3# 8.12 5.97 2.13 0.40 
Firmicutes Clostridia Lachnospiraceae GCA-900066755# 1.89 1.56 0.51 0.57 
Bacteroidetes Bacteroidia Marinifilaceae Butyricimonas# 24.58 26.22 5.23 0.76 
Firmicutes Clostridia Ruminococcaceae NA# 776.35 746.43 79.88 0.78 
Firmicutes Clostridia Lachnospiraceae Coprococcus_1# 181.22 188.32 23.13 0.79 
Firmicutes Clostridia Family_XIII NA# 2.23 2.04 0.62 0.83 
Firmicutes Clostridia Lachnospiraceae Roseburia# 480.41 499.21 78.37 0.87 
Firmicutes Clostridia Ruminococcaceae Ruminococcus_2# 1233.61 1217.96 142.3
8 
0.89 
Firmicutes Clostridia Lachnospiraceae Lachnospira 546.75 800.77 108.0
0 
0.11 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-013 121.20 167.57 25.67 0.11 
Firmicutes Clostridia Lachnospiraceae Tyzzerella 2.83 1.71 0.65 0.13 
Actinobacteria Coriobacteriia NA NA 16.33 12.24 3.04 0.13 
Firmicutes Clostridia Peptostreptococcaceae Romboutsia 318.28 200.60 53.86 0.14 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-009 7.12 4.67 1.50 0.14 
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Firmicutes Clostridia Peptococcaceae NA 2.29 3.58 0.61 0.15 
Proteobacteria Gammaproteobacteria Pasteurellaceae Haemophilus 93.83 65.94 27.52 0.15 
Actinobacteria Coriobacteriia Eggerthellaceae NA 95.20 80.95 11.11 0.15 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_UCG-008 31.22 25.32 5.06 0.16 
Firmicutes Clostridia Family_XIII Family_XIII_AD3011_group 54.59 44.70 10.09 0.16 
Firmicutes Clostridia Ruminococcaceae Candidatus_Soleaferrea 6.82 4.08 1.39 0.18 
Proteobacteria Gammaproteobacteria Burkholderiaceae Sutterella 119.28 100.68 13.34 0.18 
Firmicutes Clostridia Lachnospiraceae CAG-56 129.53 108.30 16.04 0.19 
Actinobacteria Coriobacteriia Coriobacteriales_Incertae_Sedis NA 9.06 5.99 1.60 0.19 
Proteobacteria Deltaproteobacteria Desulfovibrionaceae Bilophila 27.30 23.77 4.71 0.21 
Firmicutes Clostridia Lachnospiraceae Coprococcus_3 224.07 187.07 27.56 0.22 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-003 89.41 108.96 13.98 0.22 
Firmicutes Clostridia Lachnospiraceae Howardella 12.54 10.49 2.67 0.24 
Firmicutes Clostridia Ruminococcaceae UBA1819 23.47 9.70 8.97 0.24 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_UCG-001 116.52 149.00 27.09 0.25 
Firmicutes Erysipelotrichia Erysipelotrichaceae Merdibacter 11.55 7.83 2.77 0.25 
Bacteroidetes Bacteroidia Prevotellaceae Prevotella_7 88.13 43.88 26.66 0.25 
Proteobacteria Deltaproteobacteria Desulfovibrionaceae NA 5.57 4.36 1.09 0.26 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-010 84.22 71.79 10.01 0.26 
Firmicutes Clostridia Ruminococcaceae Fournierella 6.28 4.60 1.16 0.27 
Firmicutes Clostridia Family_XIII Mogibacterium 1.57 0.60 0.60 0.27 
Firmicutes Clostridia Lachnospiraceae Hungatella 4.93 2.33 1.83 0.27 
Firmicutes Clostridia Ruminococcaceae Subdoligranulum 3311.80 2935.40 466.3
7 
0.32 
Firmicutes Erysipelotrichia Erysipelotrichaceae Holdemanella 265.34 296.06 50.79 0.32 
Bacteroidetes Bacteroidia Prevotellaceae Paraprevotella 30.78 29.03 5.20 0.34 
Proteobacteria Gammaproteobacteria Enterobacteriaceae Klebsiella 22.57 76.22 38.88 0.34 
Firmicutes Clostridia Ruminococcaceae Ruminiclostridium_6 235.78 183.68 48.31 0.35 
Firmicutes Negativicutes Acidaminococcaceae Acidaminococcus 20.93 11.89 6.68 0.35 
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Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_ND3007_group 377.15 409.98 36.50 0.35 
Bacteroidetes Bacteroidia Marinifilaceae Odoribacter 47.55 53.98 6.33 0.36 
Actinobacteria Actinobacteria Bifidobacteriaceae Bifidobacterium 942.23 1163.59 178.2
9 
0.37 
Firmicutes Clostridia Ruminococcaceae Fecalibacterium 5154.16 4869.92 399.5
2 
0.37 
Firmicutes Bacilli Streptococcaceae Lactococcus 11.00 15.63 4.44 0.38 
Firmicutes Clostridia Lachnospiraceae Coprococcus_2 689.90 804.51 140.2
6 
0.38 
Actinobacteria Coriobacteriia Eggerthellaceae Enterorhabdus 66.77 58.18 10.73 0.41 
Firmicutes Clostridia Lachnospiraceae GCA-900066575 17.58 15.46 2.08 0.44 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-002 1131.35 1052.08 146.6
5 
0.44 
Firmicutes Erysipelotrichia Erysipelotrichaceae Erysipelotrichaceae_UCG-003 226.99 192.24 41.24 0.44 
Firmicutes Clostridia Peptostreptococcaceae Terrisporobacter 62.71 81.48 21.69 0.45 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_NK4A136_group 457.00 383.24 68.29 0.45 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-014 841.07 754.52 108.5
8 
0.47 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_AC2044_group 10.98 18.65 7.50 0.48 
Firmicutes Erysipelotrichia Erysipelotrichaceae Turicibacter 91.35 111.28 23.94 0.48 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-011 1.14 1.56 0.42 0.48 
Firmicutes Negativicutes Acidaminococcaceae Phascolarctobacterium 181.57 198.77 41.31 0.50 
Firmicutes Bacilli Carnobacteriaceae Granulicatella 0.83 0.60 0.25 0.50 
Firmicutes Clostridia Ruminococcaceae Flavonifractor 12.46 11.17 1.75 0.51 
Firmicutes NA NA NA 10.54 9.57 2.29 0.51 
Actinobacteria Coriobacteriia Eggerthellaceae Gordonibacter 1.35 1.70 0.37 0.52 
Firmicutes Clostridia Ruminococcaceae Caproiciproducens 7.87 6.98 1.59 0.53 
Firmicutes Clostridia Ruminococcaceae Ruminococcaceae_UCG-004 50.34 44.88 7.47 0.54 
Firmicutes Clostridia Ruminococcaceae Phocea 0.47 0.68 0.25 0.55 
Firmicutes Clostridia Ruminococcaceae Anaerotruncus 6.00 5.36 2.19 0.59 
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Firmicutes Clostridia Lachnospiraceae NA 1847.16 1918.00 114.9
9 
0.62 
Firmicutes Clostridia Ruminococcaceae GCA-900066225 5.69 4.94 1.27 0.63 
Firmicutes Clostridia Christensenellaceae Christensenellaceae_R-7_group 1502.70 1417.41 160.7
8 
0.63 
Firmicutes Clostridia Ruminococcaceae Intestinimonas 76.14 71.03 10.33 0.63 
Firmicutes Clostridia Lachnospiraceae Eisenbergiella 2.93 2.23 1.06 0.63 
Firmicutes Clostridia Lachnospiraceae Tyzzerella_3 22.09 27.75 11.21 0.64 
Actinobacteria Coriobacteriia Atopobiaceae Olsenella 12.79 13.86 3.33 0.65 
Firmicutes Clostridia Ruminococcaceae Ruminiclostridium_9 104.62 109.01 11.21 0.65 
Firmicutes Clostridia Christensenellaceae NA 214.41 243.77 60.02 0.65 
Firmicutes Erysipelotrichia Erysipelotrichaceae Catenibacterium 284.89 243.09 70.12 0.66 
Firmicutes Clostridia Lachnospiraceae Anaerostipes 507.04 553.95 84.98 0.66 
Firmicutes Clostridia Ruminococcaceae Oscillibacter 60.39 53.86 11.86 0.68 
Firmicutes Clostridia Lachnospiraceae Sellimonas 3.94 4.37 0.77 0.68 
Actinobacteria Actinobacteria Actinomycetaceae Actinomyces 20.75 19.50 3.32 0.70 
Firmicutes Clostridia Ruminococcaceae Ruminococcus_1 456.75 501.79 83.25 0.71 
Firmicutes Clostridia Ruminococcaceae Ruminiclostridium 1.36 1.54 0.37 0.73 
Firmicutes Negativicutes Veillonellaceae Veillonella 93.28 106.86 33.72 0.73 
Firmicutes Clostridia Lachnospiraceae Blautia 2789.05 2726.91 167.0
0 
0.74 
Bacteroidetes Bacteroidia Barnesiellaceae Coprobacter 4.93 5.36 1.77 0.75 
Proteobacteria Gammaproteobacteria Burkholderiaceae Oxalobacter 4.41 4.02 1.04 0.75 
Actinobacteria Coriobacteriia Coriobacteriaceae Collinsella 722.44 688.30 80.96 0.76 
Firmicutes Clostridia Ruminococcaceae Pseudoflavonifractor 2.55 2.34 0.66 0.76 
Firmicutes Clostridia Lachnospiraceae Lachnoclostridium 263.34 252.68 40.26 0.79 
Firmicutes Erysipelotrichia Erysipelotrichaceae Coprobacillus 3.91 5.07 3.25 0.80 
Firmicutes Clostridia Ruminococcaceae CAG-352 242.31 290.23 155.1
9 
0.81 
Firmicutes Clostridia Lachnospiraceae Agathobacter 2661.19 2575.52 373.5
8 
0.81 
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Lentisphaerae Lentisphaeria Victivallaceae Victivallis 4.60 4.46 2.12 0.86 
Proteobacteria Alphaproteobacteria NA NA 45.86 48.97 20.09 0.89 
Firmicutes Bacilli Streptococcaceae Streptococcus 450.58 469.33 124.0
6 
0.92 
Actinobacteria Coriobacteriia Eggerthellaceae Slackia 20.54 20.13 3.02 0.92 
Firmicutes Erysipelotrichia Erysipelotrichaceae Holdemania 3.49 3.40 0.83 0.93 
Firmicutes Clostridia Lachnospiraceae Lachnospiraceae_UCG-004 79.11 80.21 10.32 0.94 
Firmicutes Clostridia NA NA 307.27 303.76 104.1
4 
0.95 
Firmicutes Clostridia Ruminococcaceae Papillibacter 1.95 1.91 0.53 0.95 
Firmicutes Clostridia NA NA 57.60 56.64 28.21 0.97 
Firmicutes Clostridia Peptostreptococcaceae NA 1.84 1.87 0.57 0.97 
Lentisphaerae Lentisphaeria vadinBE97 NA 1.76 1.75 0.79 0.99 
Bacteroidetes Bacteroidia Bacteroidaceae Bacteroides 3890.86 3885.54 358.3
2 
0.99 
Firmicutes Erysipelotrichia Erysipelotrichaceae Erysipelatoclostridium 7.32 7.34 1.99 0.99 
 
*The least square mean and standard error of genera abundance was obtained by mixed modelling (n=20 subjects). The effects of diet were 
evaluated using a generalized linear mixed model that included a fixed effect of diet, sequence of allocation, and their interaction. Bold letters 
denote bacterial genera that significantly differed between meat and vegetarian diets.  
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Table S9. Fecal levels of short chain fatty acids and branched chain fatty acids relative to dietary intervention.  
 Post-MD* Post-VD* SEM Percent difference 
Acetate 90.3 94.0 8.3 4.1 
Butyrate 34.0 35.7 4.9 5 
Propionate 29.1 32 3.6 9.9 
Lactate 0.64 0.3 0.3 -53.1 
Succinate 0.1 0.1 0.03 12 
Isobutyrate 3.23 3.3 0.2 2.2 
Isovalerate 2.7 2.8 0.2 5.6 
Total BCFAs 5.9 6.2 0.4 5.8 
Total SCFAs 154.0 162.0 15.0 5.2 
*The least square mean and standard error of fecal fatty acid level was obtained from mixed model (n=20 subjects). The effects of diet were 
evaluated using a generalized linear mixed model that included a fixed effect of diet, sequence of allocation, and their interaction. Percent 
difference indicates the median difference in concentration in vegetarian vs. meat diet. Total branched chain fatty acids (BCFA) = the sum of 
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Table S10. Plasma levels of selected metabolites with respect to dietary intervention. 
Metabolite Ionization m/z Retention time Post MD* Post VD SEM P Value 
Unknown 180.8988 RP- 182.8988 11.38 16843.29 14557.47 633.66 0.002 
Cysteinyl-Cysteine RP- 260.9793 0.70 6631.55 7853.38 492.19 0.066 
Lignoceric acid RP- 367.3586 9.02 36810.40 43195.67 1933.87 0.025 
dihydroxy-stearic acid RP- 375.2750 7.00 196729.93 169679.79 10085.60 0.018 
Unknown 481.2818 RP- 481.2818 6.24 16467.75 26236.58 5620.74 0.023 
PC (14:0/O-1:0) RP- 526.3512 7.12 15228.39 11015.75 906.87 0.004 
lysoPC (16:1) RP- 552.3308 6.82 13045.53 10808.43 680.58 0.009 
Unknown 570.8316 RP- 570.8316 0.63 3844.64 4421.80 299.94 0.106 
lysoPE (22:0) RP- 592.3600 7.05 12193.78 8386.79 947.67 0.011 
DG (16:0/20:3) RP- 653.4922 9.86 4283.02 5275.64 334.29 0.027 
PE (18:1/20:4) RP- 748.5318 8.85 18748.37 12565.47 1133.24 0.000 
2-Hydroxylauroylcarnitine RP- 777.5494 8.46 15513.48 13221.52 961.62 0.035 
PE (18:1/18:1) RP- 786.5671 8.89 11655.84 8956.61 733.66 0.004 
PE (20:3/18:1) RP- 810.5666 8.80 23648.56 17826.32 1149.66 <0.001 
PE (20:2/18:1) RP- 812.5822 8.96 30155.11 22896.73 1162.19 <0.001 
PC (20:2/16:0) RP- 820.5644 9.23 51624.88 44215.94 2679.98 0.066 
PE (18:0/22:5) RP- 822.5641 9.22 21394.62 16708.67 1493.55 0.040 
PC (18:1/22:4) RP- 836.5812 8.88 13050.88 10243.25 640.24 0.004 
3-[3,5-dihydroxy-4-(sulfo-
oxy)phenyl]-2-oxopropanoic acid 
RP+ 168.9820 11.48 155146.44 182929.37 6860.20 0.010 
3-Methylhistidine RP+ 170.0908 0.63 1943.89 865.23 355.01 0.025 
Hippurate RP+ 180.0651 2.90 515914.00 450011.66 58837.15 0.349 
3-Indolepropionic acid RP- 190.0867 4.39 98007.09 122411.46 17291.84 0.259 
2-Methylbutyroylcarnitine RP+ 246.1697 2.52 38209.45 32777.99 3639.34 0.181 
Subaphylline RP+ 247.1446 2.44 52076.92 118952.27 14585.80 0.002 
Acoric acid RP+ 286.2014 3.91 147642.67 215322.85 17346.72 0.002 
4-hydroxy nonenal mercapturic 
acid 
RP+ 287.1510 5.80 84412.33 40256.93 11244.85 0.012 
N-Acetylanonaine RP+ 308.1297 5.80 27288.67 9587.51 3534.59 0.001 
Fatty acid 346.1231 RP+ 346.1231 4.55 80258.08 218453.19 39899.08 0.024 
Tetracosanedione RP+ 366.3749 7.90 84840.86 45100.68 9876.02 0.008 
Uknown 464.193 RP+ 464.1931 4.60 19418.79 9724.71 2506.99 0.011 
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PC (16:0/18:1) RP+ 742.5793 8.87 39397.84 27681.81 2943.77 0.004 
PC (18:1/18:1) RP+ 768.5931 8.92 126228.97 82032.18 9985.77 <0.001 
*The least square mean and standard error of metabolite level was obtained via mixed modelling (n=21 subjects). The effects of diet were 
evaluated using a generalized linear mixed model that included a fixed effect of diet, sequence of allocation, and their interaction. Bold letters 
denote the bacterial genera that significantly differed between meat and vegetarian diets.  
DG, diacylglycerol, PE, phosphatidylethanolamine; PC, phosphatidylcholine. RP+: reverse phase chromatography positive ionization mode; RP-: 
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Table S11. Spearman correlation of bacterial genera and plasma metabolites with cardiometabolic risk factors, vegetarian diet. 
Variables Oxidized LDL TC LDL BMI Weight 
r P r P r P r P r P 
Genus Zotu1114_GCA.900066755 -0.36 0.02 -0.30 0.05 -0.38 0.01 -0.20 0.21 -0.13 0.42 
Genus Zotu74_Ruminococcaceae_NK4A214_group -0.51 0.00 -0.30 0.06 -0.37 0.02 -0.19 0.22 -0.25 0.11 
Genus Zotu822_Ruminococcaceae_UCG.007 0.24 0.13 0.26 0.10 0.36 0.02 -0.03 0.83 0.00 1.00 
Genus Zotu647_Eggerthella 0.31 0.04 0.38 0.01 0.35 0.02 0.09 0.58 0.17 0.28 
Genus Zotu62_Coprococcus_1 -0.37 0.02 -0.29 0.06 -0.33 0.03 -0.06 0.69 -0.12 0.46 
Genus Zotu87_Roseburia 0.20 0.21 0.45 0.00 0.32 0.04 -0.12 0.44 -0.06 0.72 
Genus Zotu412_Butyricimonas 0.05 0.76 0.28 0.07 0.31 0.04 0.00 0.99 0.02 0.90 
Genus Zotu10_Ruminococcus_2 -0.34 0.03 -0.23 0.14 -0.31 0.05 -0.14 0.39 -0.12 0.43 
Genus Zotu25_Escherichia.Shigella 0.29 0.06 0.38 0.01 0.31 0.05 -0.21 0.19 -0.16 0.31 
Genus Zotu152_Marvinbryantia -0.29 0.06 -0.40 0.01 -0.28 0.07 -0.35 0.03 -0.27 0.08 
Genus Zotu397_Oscillospira -0.11 0.49 -0.11 0.49 -0.28 0.07 0.00 1.00 -0.02 0.89 
Genus Zotu728_Shuttleworthia -0.43 0.00 -0.32 0.04 -0.27 0.08 -0.05 0.76 -0.10 0.53 
Genus Zotu832_Anaerofilum 0.27 0.09 0.27 0.08 0.27 0.08 -0.09 0.56 0.02 0.90 
Genus Zotu57_Parabacteroides 0.19 0.24 0.35 0.02 0.27 0.09 0.09 0.58 0.09 0.59 
Genus Zotu576_Angelakisella 0.08 0.61 0.28 0.07 0.26 0.10 0.18 0.27 0.23 0.15 
Genus Zotu239_NA -0.21 0.18 -0.28 0.08 -0.24 0.13 -0.05 0.75 0.01 0.97 
Genus Zotu398_DTU089 0.17 0.30 0.28 0.07 0.22 0.15 0.08 0.63 0.11 0.49 
Genus Zotu788_NA -0.42 0.01 -0.11 0.48 -0.20 0.20 -0.07 0.66 -0.07 0.66 
Genus Zotu63_Clostridium_sensu_stricto_1 0.02 0.89 0.11 0.50 0.20 0.21 0.28 0.07 0.30 0.05 
Genus Zotu191_Senegalimassilia 0.15 0.36 0.03 0.86 0.19 0.22 0.50 0.00 0.42 0.01 
Genus Zotu676_Hydrogenoanaerobacterium -0.32 0.04 -0.23 0.14 -0.16 0.32 0.04 0.80 -0.08 0.62 
Genus Zotu58_Butyrivibrio 0.02 0.92 -0.09 0.56 -0.15 0.34 0.31 0.05 0.30 0.06 
Genus Zotu13_Fusicatenibacter -0.17 0.29 -0.14 0.36 -0.15 0.34 -0.20 0.21 -0.14 0.36 
Genus Zotu50_Intestinibacter 0.12 0.45 0.11 0.48 0.14 0.37 0.05 0.74 0.17 0.29 
Genus Zotu307_NA 0.04 0.81 -0.21 0.18 -0.13 0.42 0.08 0.62 0.01 0.96 
Genus Zotu262_Lachnospiraceae_UCG.010 0.29 0.06 -0.11 0.49 0.13 0.42 -0.03 0.85 0.02 0.90 
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Genus Zotu145_Butyricicoccus -0.11 0.50 -0.09 0.59 -0.12 0.46 -0.04 0.82 -0.13 0.40 
Genus Zotu34_Ruminococcaceae_UCG.005 -0.29 0.07 -0.23 0.13 -0.11 0.47 0.01 0.93 -0.10 0.55 
Genus Zotu38_Alistipes -0.08 0.61 0.17 0.28 0.11 0.49 0.01 0.95 0.00 0.98 
Genus Zotu334_NA -0.21 0.18 -0.16 0.31 -0.11 0.49 0.23 0.14 0.19 0.24 
Genus Zotu481_UC5.1.2E3 0.36 0.02 0.15 0.33 0.10 0.52 -0.23 0.14 -0.20 0.21 
Genus Zotu512_NA -0.05 0.73 0.07 0.65 0.10 0.53 0.07 0.67 0.07 0.66 
Genus Zotu169_Lachnospiraceae_FCS020_group 0.25 0.11 0.07 0.66 0.10 0.53 -0.03 0.83 0.02 0.90 
Genus Zotu357_Family_XIII_UCG.001 0.35 0.02 0.12 0.46 0.10 0.53 0.03 0.84 -0.05 0.75 
Genus Zotu629_DNF00809 -0.05 0.76 -0.20 0.21 -0.09 0.56 0.16 0.31 0.09 0.57 
Genus Zotu180_Lactobacillus 0.04 0.81 0.21 0.18 0.09 0.56 0.19 0.22 0.11 0.51 
Genus Zotu36_NA -0.39 0.01 -0.17 0.27 -0.07 0.65 0.15 0.33 0.12 0.47 
Genus Zotu35_Dialister -0.15 0.34 -0.18 0.24 -0.07 0.66 0.13 0.41 -0.01 0.95 
Genus Zotu364_Negativibacillus 0.05 0.74 0.08 0.63 0.07 0.66 0.04 0.82 0.14 0.39 
Genus Zotu114_Methanobrevibacter -0.16 0.32 -0.25 0.11 -0.07 0.66 0.05 0.77 -0.03 0.83 
Genus Zotu279_Adlercreutzia 0.02 0.88 0.13 0.40 0.07 0.66 0.20 0.20 0.18 0.24 
Genus Zotu2541_NA 0.12 0.44 0.17 0.28 0.04 0.78 -0.03 0.84 -0.02 0.88 
Genus Zotu399_NA -0.29 0.06 0.05 0.75 -0.04 0.79 -0.07 0.67 -0.12 0.45 
Genus Zotu12_Akkermansia -0.14 0.37 -0.09 0.57 -0.03 0.85 0.13 0.42 0.05 0.76 
Genus Zotu215_Parasutterella -0.15 0.35 0.12 0.46 -0.03 0.86 -0.10 0.53 -0.23 0.14 
Metabolite PC (18:1/18:1) 0.55 0.00 0.21 0.19 0.33 0.04 -0.14 0.38 -0.17 0.29 
Metabolite lysoPC (16:0) 0.39 0.01 0.39 0.01 0.29 0.07 -0.01 0.95 0.01 0.97 
Metabolite DG (16:0/20:3) -0.35 0.03 -0.47 0.00 -0.44 0.01 -0.31 0.05 -0.33 0.04 
Metabolite lysoPC (16:1) 0.35 0.03 0.38 0.01 0.25 0.12 0.19 0.23 0.14 0.40 
Metabolite PE (18:0/22:5) 0.34 0.03 0.28 0.08 0.37 0.02 -0.06 0.69 -0.17 0.29 
Metabolite PC (14:0/O-1:0) 0.25 0.12 0.27 0.09 0.23 0.15 -0.03 0.87 -0.13 0.43 
Metabolite Subaphylline -0.25 0.13 0.01 0.94 -0.08 0.61 -0.06 0.71 -0.08 0.60 
Metabolite PC (20:2/16:0) 0.23 0.15 0.28 0.08 0.28 0.08 0.04 0.80 0.00 0.99 
Metabolite PC (16:0/18:1) 0.23 0.16 0.19 0.25 0.12 0.47 -0.30 0.06 -0.26 0.11 
Metabolite lysoPE (22:0) 0.21 0.18 0.20 0.22 0.21 0.18 -0.08 0.62 -0.09 0.59 
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Metabolite Acoric acid -0.19 0.23 -0.30 0.06 -0.27 0.09 -0.08 0.64 -0.07 0.66 
Metabolite Tetracosanedione 0.18 0.26 0.09 0.60 0.19 0.23 -0.01 0.97 0.00 0.99 
Metabolite PE (20:2/18:1) 0.16 0.32 -0.16 0.34 -0.07 0.65 -0.21 0.19 -0.31 0.05 
Metabolite 2-Hydroxylauroylcarnitine 0.15 0.35 0.39 0.01 0.25 0.12 0.26 0.11 0.14 0.39 
Metabolite Hippurate 0.15 0.36 0.28 0.09 0.13 0.42 0.33 0.04 0.24 0.14 
Metabolite 3-Indolepropionic acid 0.14 0.38 0.15 0.34 0.25 0.12 0.24 0.14 0.15 0.34 
Metabolite Unknown 464.193 -0.11 0.50 0.13 0.43 0.17 0.28 0.06 0.71 0.02 0.88 
Metabolite Unknown 481.2818 -0.10 0.55 -0.08 0.61 -0.22 0.17 0.31 0.05 0.27 0.09 
Metabolite 3-[3.5-dihydroxy-4-(sulfoxy)phenyl]-2-
oxopropanoic acid 
0.10 0.55 0.15 0.34 0.02 0.89 0.15 0.34 0.21 0.19 
Metabolite N-Acetylanonaine 0.10 0.56 0.35 0.03 0.22 0.17 0.16 0.32 0.18 0.27 
Metabolite Unknown180.8988 0.09 0.57 0.02 0.91 -0.08 0.61 0.36 0.02 0.24 0.14 
Metabolite 3-Methylhistidine -0.09 0.58 -0.10 0.55 -0.16 0.34 -0.13 0.43 -0.20 0.22 
Metabolite PE (18:1/18:1) -0.09 0.59 -0.10 0.56 -0.11 0.49 -0.20 0.22 -0.27 0.09 
Metabolite 2-Methylbutyroylcarnitine 0.08 0.63 0.04 0.81 -0.05 0.78 -0.24 0.14 -0.30 0.06 
Metabolite Cysteinyl-Cysteine -0.07 0.65 -0.09 0.58 -0.13 0.42 0.36 0.02 0.20 0.21 
Metabolite Unknown570.8316 -0.07 0.67 0.05 0.74 -0.12 0.47 0.06 0.70 0.09 0.57 
Metabolite PE (18:1/20:4) -0.04 0.81 0.13 0.43 0.07 0.66 0.07 0.65 0.01 0.94 
Metabolite 4-hydroxy nonenal mercapturic acid 0.03 0.84 0.22 0.17 0.17 0.29 0.21 0.19 0.17 0.30 
Metabolite PC (18:1/22:4) 0.03 0.87 0.06 0.72 0.06 0.71 -0.12 0.46 -0.26 0.11 
Metabolite dihydroxy-stearic acid 0.02 0.91 0.20 0.22 0.12 0.44 0.14 0.38 0.20 0.23 
Metabolite PE (20:3/18:1) 0.01 0.94 -0.12 0.48 -0.08 0.60 -0.22 0.17 -0.28 0.08 
Metabolite Fatty acid 346.1231 0.00 1.00 0.07 0.67 0.16 0.32 0.16 0.32 0.19 0.23 
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Figure S2. Structure of the effective dataset representing the within-individual variations between treatments. The effective dataset was 
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Figure S3. Difference in microbiota diversity and plasma metabolome of baseline and wash-out period. 
The between-diet distance in gut microbiota for all samples was assessed using (A) unweighted UniFrac, (B) weighted UniFrac and (C) Bray-Curtis. 
Random forest modeling of plasma metabolome between baseline and wash-out was conducted; model performance is shown in D. No 
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Figure S4. Time series analysis and mean changes in oxidized LDL according to dietary intervention. 
Within-group change P-value was calculated with paired t-test. **P<0.01. LDL-C, low-density lipoprotein cholesterol; MD, meat diet; VD, 
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Figure S5. Time series analysis and mean changes in lipid profile according to dietary intervention. 
Within-group change P-value was calculated with paired t-test. *P<0.05; **P<0.01; ***P<0.001. HDL-C, high-density lipoprotein cholesterol; 
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Figure S6. Relative abundance of gut microbiota at phylum (A) and genus level (B) representing the microbiome pattern across individuals 
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Observed species and Faith’s Phylogentic Diversity (A), PCoA plots for Bray-Curtis dissimilarity (B), Unweighted UniFrac (C), and weighted UniFrac 








Figure S8. Prediction of optimal selected bacteria genera using the random forest modeling 
based multilevel data analysis.  
 
Samples are matched row-wise between upper and lower half for the treatment-effect 
matrix. Prediction estimates are shown in grey for each repetition of repeat double cross-
validation and in black for the prediction estimates averaged over all repetitions. Misclassified 
samples are circled. The models showed high accuracy in discriminating the vegetarian diet 
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Figure S9. Prediction of optimally selected metabolites using the random forest modeling 
based multilevel data analysis of plasma metabolome by ESI+ (A) and ESI- (B).  
Samples are matched row-wise between upper and lower half for the treatment effect matrix. 
Prediction estimates are shown in grey for each repetition of repeat double cross-validation 
and in black for the estimates averaged over all repetitions. Misclassified samples are circled. 
The models showed high accuracy in discriminating the vegetarian diet from the meat diet. 
Figure S10. Time series analysis and mean changes in TMAO, Choline, L-carnitine and Acetyl-
carnitine according to dietary intervention.  
Within-group change P-value was calculated with paired t-test. *P<0.05; **P<0.01; 
***P<0.001. µM, micromolar concentration.  MD, meat diet; TMAO, trimethylamine N-oxide; 
VD, vegetarian diet. 
Figure S11. Correlations between plasma concentrations of trimethylamine N-oxide 
(TMAO), choline, L-carnitine and acetyl-carnitine and cardiometabolic risk factors (A) or the 
microbial genera (B) that were optimally selected to distinguish the vegetarian diet and the 
isocaloric meat diet using multilevel random forest algorithm.  
Only microbial genera that were significantly correlated with at least one of plasma 
metabolites are present (B). 
*P<0.05; **P<0.01; ***P<0.001. None of the correlations remained significant after false-
discovery-rate correction for multiple testing. 
Figure S12. Baseline gut microbiota associated with response to diet with respect to BMI. 
Subjects with lower BMI post-VD compared with post-MD were defined as responders. 
Patients who had higher BMI after VD than MD were categorized as non-responders.  
Figure S13. Baseline plasma metabolome showed no association with diet-related change in oxidized LDL-C (A and B) or BMI (C and D). 
Accuracy of baseline plasma metabolome in discriminating responders from non-responders using random forest algorithm (A and C) and results 
from permutation analysis (B and D) is presented.  
